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A B S T R A C T
Background
Patients with schizophrenia smoke more heavily than the general population and this contributes to their higher morbidity and mortality
from smoking-related illnesses. It remains unclear what interventions can help them to quit or reduce smoking.
Objectives
To evaluate the benefits and harms of diFerent treatments for nicotine dependence in schizophrenia.
Search methods
We searched the Cochrane Tobacco Addiction Group Specialized Register and electronic databases including MEDLINE, EMBASE and
PsycINFO from inception to April 2010.
Selection criteria
We included randomized trials for smoking cessation or reduction, comparing any pharmacological or non-pharmacological intervention
with placebo or with another therapeutic control in adult smokers with schizophrenia or schizoaFective disorder.
Data collection and analysis
Two reviewers independently assessed the eligibility and quality of trials and extracted data. Outcome measures included smoking
abstinence, reduction in the amount smoked and any change in mental state. We extracted abstinence and reduction data at the end of
treatment and at least six months aJer the intervention. We used the most rigorous definition of abstinence or reduction and biochemically
validated data where available. Any reported adverse events were noted. Where appropriate, we pooled data using a random eFects model.
Main results
We included 21 trials (11 trials of smoking cessation; four trials of smoking reduction; one trial for relapse prevention; five trials reported
smoking outcomes for interventions aimed at other purposes). Seven trials compared bupropion with placebo; meta-analysis showed
that smoking cessation rates aJer bupropion were significantly higher than placebo at the end of treatment (seven trials, N=340; risk ratio
[RR] 2.84; 95% confidence interval [CI] 1.61 to 4.99) and aJer six months (five trials, N=214, RR 2.78; 95% CI 1.02 to 7.58). Expired carbon
monoxide (CO) level and the number of cigarettes smoked daily were significantly lower with bupropion at the end of therapy but not aJer
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six months.  There were no significant diFerences in positive, negative and depressive symptoms between bupropion and placebo group.
There was no report of major adverse event such as seizures with bupropion.
Contingent reinforcement (CR) with money may increase smoking abstinence rates and reduce the level of smoking in patients with
schizophrenia. However, it is uncertain whether these benefits are maintained in the longer term. There was no evidence of benefit for the
few trials of other pharmacological therapies (including nicotine replacement therapy (NRT)) and psychosocial interventions in helping
smokers with schizophrenia to quit or reduce smoking.
Authors' conclusions
Bupropion increases smoking abstinence rates in smokers with schizophrenia, without jeopardising their mental state. Bupropion may
also reduce the amount these patients smoke. CR may help this group of patients to quit and reduce smoking. We failed to find convincing
evidence that other interventions have a beneficial eFect on smoking behaviour in schizophrenia.
P L A I N   L A N G U A G E   S U M M A R Y
Are there any e5ective interventions to help individuals with schizophrenia to quit or to reduce smoking?
People with schizophrenia are, very oJen, heavy smokers. It is uncertain whether treatments that have been shown to help other groups
of people to quit smoking are also eFective for people with schizophrenia. In this review, we found that bupropion (an antidepressant
medication previously shown to be eFective for smoking cessation) helps patients with schizophrenia to quit or to reduce smoking. The
eFect was clear at the end of the treatment and it may also be maintained aJer six months. Patients who used bupropion in the trials did
not experience any major adverse eFect and their mental state was stable during the treatment. Smokers with schizophrenia who receive
money as a reward for quitting may have a higher rate of stopping smoking whilst they get payments. However, there is no evidence that
they will remain abstinent aJer the reward stops. There was too little evidence to show whether other treatments like nicotine replacement
therapy and psychosocial interventions are helpful.
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Summary of findings for the main comparison.   Applicability in clinical practice - projected numbers of people with schizophrenia per hundred
patients treated with smoking cessation therapies (smoking abstinence at the end of the trial and at follow-up a:er 6 months)
Smoking abstinence at the end of trial (per 100 patients) Smoking abstinence at follow-up after 6 months (per 100 patients)Comparison
Number of
trials
Interven-
tion
Control Difference * Number
needed#
Number
of trials
Interven-
tion
Con-
trol
Difference * Number
needed#
Bupropion vs.
placebo
7 22 8 ↓14
(↓5 to ↓31)
7
(3 to 20)
5 10 4 ↓6
(0 to ↓24)
17
(4 to 1350)
TNP vs. placebo Data not combined because of heterogeneity of studies No trial found
CR + TNP vs. mini-
mal
1 50 10 ↓40 3 No follow-up data available
* calculated as absolute risk reduction/increase per 100 people treated, using the rate in control (comparator) arms of trials, with the summary RR applied to calculate the
expected absolute risk reduction/ increase for the
investigative arms of trials (95% confidence intervals in bracket)
‘ns’ = diFerence not statistically significant (i.e. summary risk ratio confidence intervals cross 1.00).
# Number needed to be treated with the intervention to cause one person to experience diFerence in the direction noted. Number needed not given where diFerence between
the intervention and the comparator arm was not significantly diFerent (95% confidence intervals in bracket)
 
 
Summary of findings 2.   Applicability in clinical practice - smoking reduction at the end of the trial and at follow-up a:er 6 months among people
with schizophrenia treated with smoking cessation therapies
Expired CO level at the end of trial (ppm) Expired CO level at follow-up after 6 months (ppm)Comparison
Number of tri-
als
intervention control Difference Number of
trials
Intervention Control Difference
Bupropion vs. placebo 3 12.9 20.3 ↓7.0
(↓2.7 to ↓11.4)
3 18.8 22.7 ns
TNP vs. placebo Data not combined because of heterogeneity of studies No trial found
CR + TNP vs. minimal 1 17.7 27.5 ↓9.8 No follow-up data available
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B A C K G R O U N D
Schizophrenia is a chronic and severe mental illness aFecting
approximately one per cent of the general population
(American Psychiatric Association 1994). A meta-analysis of 42
epidemiological studies across 20 diFerent countries shows that
people with schizophrenia have more than five times the odds
of current smoking than the general population, and smoking
cessation rates are much lower in smokers with schizophrenia
compared with the general population (de Leon 2005a).    In
addition, smokers with schizophrenia smoke more heavily and
extract more nicotine from each cigarette (Olincy 1997; Kelly 1999;
de Leon 2005a; Williams 2005). People with schizophrenia have a
shorter life expectancy than the general population, and chronic
cigarette smoking has been suggested as a major contributing
factor to higher morbidity and mortality from malignancy and,
cardiovascular and respiratory diseases in this group of patients
(Brown 2000; Lichtermann 2001). Tobacco use among individuals
with schizophrenia is financially costly; a study has shown that it
consumed 27% of the monthly income of those residing in a high
tobacco tax state (Steinberg 2004).
Heavy smoking in patients with schizophrenia has been reported
to be associated with more positive symptoms, increased
substance misuse, more frequent psychiatric hospitalisation and
a higher suicide risk (GoF 1992; Ziedonis 1994; Workgroup on
Substance Use Disorders 2006). Tobacco smoking also increases
the metabolism of some antipsychotic medications (Desai 2001)
and some patients may use tobacco to alleviate the side eFects
of neuroleptic medications. Indviduals with schizophrenia oJen
have impairment in their cognitive function including diFiculty in
filtering out unnecessary information (Kumari 2002), secondary
to abnormalities in the sensorimotor gating. Cigarette smoking
appears to improve sensory gating in patients with schizophrenia
(Adler 1998). Hence, patients with schizophrenia may use cigarette
smoking to improve their cognitive function. In addition to the
cognitive deficits of frontal executive function and in attention
among individuals with schizophrenia, depressive symptoms, drug
misuse, disorganized thinking and poor task persistence may also
explain their lower motivation and greater diFiculty for smoking
cessation (Culhane 2008; Moss 2009). Patients with schizophrenia
may be ambivalent about giving up smoking, as there are few
role models of ex-smokers and less specific support available for
quitting smoking. Furthermore, smoking is sometimes condoned
in mental health setting and in the past cigarettes were used in
token economies to reinforce positive patient behaviour (Gustafson
1992s).
Tobacco control specialists and healthcare providers previously
have not oFered tobacco dependence treatment to patients with
schizophrenia, probably secondary to stigma, lack of information,
or perceived hopelessness regarding abstinence (Williams 2006).
More recent initiatives have aimed to improve the physical health
of those with schizophrenia, and guidelines for smoking cessation
interventions for smokers with schizophrenia have now been
published (Zwar 2007; Fiore 2008; Dixon 2009; Buchanan 2009).
Smokers with schizophrenia have a more severe nicotine
dependence compared to smokers without schizophrenia (de Leon
2005a). Hence, interventions may not be as eFective as they have
shown to be in the general population. We also considered the
safety of these interventions, in particular those that involve drug
therapy. Some of the pharmacological treatments for nicotine
dependence act on neurotransmission. For example, previous
smoking cessation guidelines do not recommend the use of
bupropion in smokers with schizophrenia because there may be
a theoretical risk of psychotic relapse if bupropion, a dopamine
agonist, is used among patients with schizophrenia (Strasser 2001).
Moreover, drug treatment for smoking cessation and reduction
may interact with and alter the eFectiveness of the antipsychotic
medications, which are commonly used among patients with
schizophrenia for their illness. In addition, nicotine withdrawal
can cause symptoms like depression, anxiety, irritability. All these
factors may contribute to changes in the mental state of these
patients, and the extent of the change in the mental state remains
unclear. The aim of this review is to summarise existing evidence
for diFerent interventions in smoking cessation and reduction for
patients with schizophrenia.
O B J E C T I V E S
This review addressed the following objectives:
1. To examine the eFicacy of diFerent interventions (alone or in
combination with other interventions) on smoking cessation in
individuals with schizophrenia.
2. To examine the eFicacy of diFerent interventions (alone or in
combination with other interventions) on smoking reduction in
individuals with schizophrenia.
3. To assess any harmful eFect of diFerent interventions for
smoking cessation on the mental state of patients with
schizophrenia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized controlled trials (RCT) or quasi-
randomized controlled trials.
Types of participants
We included adult smokers with a current diagnosis of
schizophrenia according to the criteria of the International
Classification of Diseases (ICD) (World Health Organisation 2003) or
Diagnostic and Satistical Manual of Mental Disorders (DSM)
(American Psychiatric Association 1994).  Smokers with a diagnosis
of schizoaFective disorder were also included, because certain
core symptoms are the same as in schizophrenia. Patients with
a diagnosis of schizophrenia or schizoaFective disorder who
had other substance misuse disorder or additional psychiatric
disorders were not excluded, as individuals with schizophrenia
have high prevalence of substance misuse disorders (Dixon 1999).
If a study was conducted in a group of participants with mixed
psychiatric diagnoses, that trial was included only when separate
data for subjects with schizophrenia or schizoaFective disorder
were available. We included subjects who may or may not have
expressed an interest to stop or reduce smoking. We reported
whether or not participants in a study wanted to stop or reduce
smoking.
Interventions for smoking cessation and reduction in individuals with schizophrenia (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Types of interventions
We included both pharmacological and non-pharmacological
interventions (alone or in combination) specific to smoking
cessation or reduction.  Interventions intended for another purpose
(e.g. antipsychotics for treating schizophrenia) were included if
smoking abstinence or reduction outcomes were reported. We
reported the results of these trials separately and they did not
contribute to any meta-analysis, since they were not designed
to test the eFicacy of the intervention for smoking cessation or
reduction. The control condition could be another intervention
(pharmacological or non-pharmacological), placebo, or usual care.
Types of outcome measures
Primary outcomes
Smoking abstinence at longest follow up
The primary outcome was abstinence from smoking assessed at
least six months from the start of the intervention, according
to the "Russell Standard" (a common standard for outcome
criteria in smoking cessation trials) (West 2005). The United States
Department of Health and Human Services (USDHHS) Tobacco Use
and Dependence Guideline Panel also suggested a minimum of a
six-month period as an adequate period of abstinence to assess
treatment diFerences in the longer term (Fiore 2008). Abstinence
could be assessed by self report or with biochemical verification.
For data synthesis, we chose the strictest definition of abstinence in
each trial, preferring sustained abstinence over point prevalence if
both were reported. In studies that used biochemical validation of
abstinence, only people whose self-reports could be validated were
classified as abstinent.
Change in mental state
Change in mental state was measured by change in positive
symptoms (e.g. hallucinations, delusions), negative symptoms (e.g.
anhedonia, avolition), and depressive symptoms.
Secondary outcomes
Smoking abstinence at the end of the intervention
This was measured as for the primary abstinence outcome.
Reduction of smoking behaviour or dependence
This was assessed at the end of the intervention and during the
follow-up period aJer the end of the intervention, if data was
available. Measures could include any of the following: percentage
change in cigarettes per day (CPD) from baseline level; absolute
number of cigarettes foregone; incidence of achieving at least a
50% reduction in CPD; reduction of expired CO level; or reduction of
scores on scale measures of nicotine dependence (e.g. Fagerstrom
Test for Nicotine Dependence (FTND)).
Other adverse events
Any other adverse events reported were also recorded and
assessed.
Search methods for identification of studies
Electronic searches
The specialized register of the Cochrane Tobacco Addiction group
was searched in June 2009 and again in March 2010 using the
topic related free-text term 'schiz*'. See the Specialized Register
section of the Tobacco Addiction Group Module in the Cochrane
Library for search strategies for CENTRAL (the Cochrane Central
Register of Controlled Trials), MEDLINE, EMBASE, PsycINFO and
Web of Science and dates of searches. CENTRAL was searched in the
Cochrane Library 2009 Issue 2 using the strategy ((SR-SCHIZ) and
(smoking):ti,ab,kw) AND NOT (SR-TOBACCO).
In addition, we searched the following electronic databases in May
2009 and again in April 2010:
1. MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations
via OVID (1950 onwards)
2. EMBASE via OVID (1980 onwards)
3. PsycINFO via OVID (1806 onwards)
4. CINAHL (1979 onwards)
5. ISI Web of Science with Conference Proceedings (1900 onwards)
6. BIOSIS Previews (1969 onwards)
We included all data available up to the last date of search and
in any language. We included search terms for schizophrenia,
smoking and randomized trials.  For schizophrenia, we used the
search terms used by the Cochrane Schizophrenia Group.  For
smoking cessation and reduction, we used search terms defined
by the Cochrane Tobacco Addiction Group, with some modification
to focus on interventions for both smoking cessation and
reduction.  To identify randomized trials, we used the search
strategies suggested in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2008). Full search strategies for
databases are listed in the appendix of this review (Appendix 1;
Appendix 2; Appendix 3).
Searching other resources
We checked the reference lists of retrieved studies for additional
relevant information.  We also searched the following online
clinical trials registers to identify potential ongoing and
unpublished trials: (1) World Health Organisation International
Clinical Trials Registry Platform Search Portal (http://apps.who.int/
trialsearch); (2) ClinicalTrials.gov register (www.clinicaltrials.gov);
(3) The Australian New Zealand Clinical Trials Registry
(www.anzctr.org.au); (4) International Standard Randomised
Controlled Trial Number Register (www.controlled-trials.com/
isrctn/) and (5) UK Clinical Trials Gateway (www.controlled-
trials.com/ukctg/). Where duplicate reporting of the same trial was
suspected, we attempted to contact authors for clarification.   If
duplication was confirmed, we used the full publication together
with any other related publications for additional information.
Data collection and analysis
Selection of studies
Two authors (DTT & ACW) screened the titles and abstracts
identified by the search independently, and decided on the
possible reports to be included. Full text reports of all potentially
relevant trials were obtained and examined by both authors
to decide whether the studies fulfilled the inclusion criteria.
Any disagreement between the authors was resolved through
discussion. All studies excluded at this stage were reported in the
characteristics of excluded studies section.
Interventions for smoking cessation and reduction in individuals with schizophrenia (Review)
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Data extraction and management
Two authors (DTT & MP) independently extracted data from all
included trials with a specifically designed data extraction form.
Information extracted included the following:
1. Methodology - including the inclusion and exclusion criteria,
method of randomization and other design features and setting
of the trial.
2. Demographics of participants - including severity of tobacco
dependency, concurrent medication used and severity of
schizophrenic illness.
3. Details of the interventions - including any target quit date set.
4. Outcome measures - including the definition of abstinence and
length of follow up and measurements used, including any
biochemical verification.
We attempted to contact the authors of the reports if there were any
uncertainties or possible duplicate reporting of the same patient
group, or for clarification of the study design and results. We sought
separate data for participants with schizophrenia or schizoaFective
disorder in trials that recruited people with a wider range of
psychiatric diagnoses. Any disagreement between the authors was
resolved through discussions or consultation with author ACW.
We categorised trials according to the primary aim of the study
(i.e. smoking cessation, smoking reduction, or intervention with
other aims). To group trials by category in the Characteristics of
included studies we used the prefixes *, + , and ^  as part of the study
identifiers. For each category, we grouped the trials according to
the specifics of the intervention.
Assessment of risk of bias in included studies
During data extraction, two authors (DTT & MP) also independently
assessed each trial for risk of bias according to the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins
2008). We recorded sequence generation during randomization,
concealment of allocation, blinding, completeness of outcome data
(including use of intention-to-treat (ITT) analysis) and selective
outcome reporting for each trial. Other potential sources of bias
were also identified. Each trial was categorised as low, uncertain or
high risk of bias of each domain, based on the standards described
in the Cochrane Handbook.
Measures of treatment e5ect
We calculated summary estimates for the extracted data. Results
for dichotomous outcomes were expressed as risk ratios (RR). RR
was calculated as: (number of subjects with the outcome
in intervention group / number of subjects randomized to
intervention group) / (number of subjects with the outcome
in the control group / number of subjects randomized to the
control group). An RR greater than one favoured the intervention
group.  Results for continuous outcomes were expressed as
mean diFerence (MD) where measured with the same scale,
or standardised mean diFerence (SMD) where measured with
diFerent scales. A summary MD or SMD below zero favoured the
intervention group in all continuous outcome measures.
Dealing with missing data
We attempted to contact trial authors for any missing data. For
data synthesis, where no additional information was forthcoming,
we assumed any missing data as failure to achieve the outcome.
The potential impact of the missing data was also addressed in the
risk of bias table for each study. We did not include trials for meta-
analysis of continuous outcomes if there was no standard deviation
(SD) or other estimate of variability available.
Assessment of heterogeneity
We examined statistical heterogeneity among trials with the
Cochran Q test and by calculating the I2 statistic. The I2 statistic
describes the percentage of the variability in the summary estimate
due to heterogeneity rather than chance (Higgins 2003).   Values
over 50% suggested moderate heterogeneity and values over 75%
suggest substantial heterogeneity.
Assessment of reporting biases
Where appropriate, potential publication bias was assessed with
funnel plots of the log risk ratio, mean diFerence or standardised
mean diFerence.
Data synthesis
Where appropriate, we performed meta-analysis of the trial data.
For abstinence and reduction, we conducted analyses with data
from six-month follow up (primary outcome) and from the end
of the intervention (secondary outcome). For change in mental
state we conducted separate analyses for positive, negative, and
depressive symptoms, using data available at the end of the
intervention.
For dichotomous outcomes, we calculated the summary estimates
using the Mantel-Haenszel method and reported the 95%
confidence intervals (CI) of the risk ratios. We calculated the
summary estimates for continuous outcomes using the inverse
variance approach, also with 95% CI. Change-from-baseline
measurements and final measurements were combined for
continuous outcomes if the MD was used to express the summary
results, following the Cochrane Handbook (Higgins 2008).
Data were pooled using the random-eFects model, although the
fixed-eFect model was also used to ensure robustness of the model
chosen and susceptibility to outliers.
Sensitivity analysis
We conducted sensitivity analysis to assess whether the estimate
of treatment eFect was influenced by the publication type
(i.e. full journal paper versus other reports such as conference
proceedings).
R E S U L T S
Description of studies
Results of the search
We identified 564 reports from the electronic search of the
databases (99 reports from MEDLINE, 264 from EMBASE, 48 from
PsycINFO, none from CINAHL, 25 from BIOSIS reviews, 47 from
ISI Web of Science with Conference Proceedings, and 81 reports
from CENTRAL and the specialized register of the Cochrane Tobacco
Addiction group) (Figure 1). We identified three further trial reports
from hand searching and 12 ongoing studies from the online
clinical trials registers and another ongoing study from hand
searching (See Characteristics of ongoing studies). AJer screening,
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we reviewed the full text of 60 reports which were considered
potentially eligible. Eight trials were excluded aJer reviewing the
full text (See Characteristics of excluded studies). We also contacted
the investigators of two trials to clarify the method of treatment
allocation, as we had concerns that these two trials were not
randomized because of the uneven number of subjects among
the treatment groups. We have not received any response; see
Characteristics of studies awaiting classification.
 
Interventions for smoking cessation and reduction in individuals with schizophrenia (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
8
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 1.   Summary of the process of identifying randomized trials for inclusion
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Figure 1.   (Continued)
 
The final review includes 21 trials; see the Characteristics of
included studies table. The primary aim of 11 trials was to
investigate an intervention for smoking cessation (studies prefixed
with an asterisk; *George 2000; *Evins 2001; *George 2002; *Evins
2005; *Baker 2006; *Evins 2007; *Gallagher 2007; *Weiner 2007;
*Williams 2007; *George 2008; *Li 2009). Four studies focused
on smoking reduction (studies prefixed with a cross; +Hartman
1991; +Dalack 1999; +Steinberg 2003; +Fatemi 2005). One trial
investigated the use of nicotine patch for relapse prevention
aJer smoking cessation (^Horst 2005). The remaining five studies
reported outcomes related to smoking abstinence or reduction but
their main aims were to evaluate the eFectiveness of interventions
for other purposes. These studies are reported separately, and do
not contribute data to any meta-analysis (McEvoy 1995; de Leon
2005b; Kelly 2008; Weinberger 2008; Sacco 2009).
Included studies
1. Trials of interventions for smoking cessation, reduction or
relapse prevention
Study and participant characteristics
There were sixteen trials in this category; most were conducted
in the United States and reported in English apart from *Baker
2006, conducted in Australia; and *Li 2009, conducted in China
and reported in Chinese. Most of the reports were published in
journals, except three trials which were only reported as letters to
editors or conference proceedings (+Fatemi 2005; *Weiner 2007;
*Williams 2007). There were three cross-over studies (+Hartman
1991; +Dalack 1999; +Fatemi 2005) with washout periods from five
days to two weeks. The relapse prevention study, ^Horst 2005,
involved an open label phase followed by a randomized controlled
trial; we only considered data from the randomized trial phase in
this review.
Most trials recruited participants from the community. *Li 2009
recruited from an in-patient unit, and +Hartman 1991 recruited
from hospitals and the community. Two studies did not report
details of recruitment (*George 2000; +Steinberg 2003).
Three trials (+Hartman 1991; *Baker 2006; *Gallagher 2007)
recruited subjects with mixed psychiatric diagnoses but data for
participants with schizophrenia or schizoaFective disorder were
available for separate analysis. Some studies explicitly excluded
participants with any active substance misuse other than nicotine
(+Dalack 1999; *Evins 2001; *George 2002; *Evins 2005; *Evins 2007;
*George 2008).
Nine trials explicitly stated that participants had expressed interest
in quitting smoking (*George 2000; *Evins 2001; *George 2002;
*Evins 2005; ^Horst 2005; *Baker 2006; *Evins 2007; *Williams 2007;
*George 2008;). +Steinberg 2003 measured changes in quitting
motivation aJer motivational interviewing and the participants
had diFerent levels of interest in quitting smoking at the baseline.
Target quit dates were set in nine studies (*George 2000; *Evins
2001; *George 2002; *Evins 2005; ^Horst 2005; *Baker 2006; *Evins
2007; *Weiner 2007; *George 2008).
Interventions
A range of interventions were evaluated. Of the studies comparing
pharmacotherapy with placebo the commonest interventions
were bupropion (*Evins 2001; *George 2002; *Evins 2005;
+Fatemi 2005; *Weiner 2007; *Li 2009) and transdermal nicotine
patch (TNP) (+Hartman 1991; +Dalack 1999; ^Horst 2005). Two
studies compared the combination of bupropion and TNP
with TNP and placebo (*Evins 2007; *George 2008). One study
compared the eFicacy of diFerent dosages of TNP (*Williams
2007). Some of the drug therapy studies provided psychosocial
interventions to all participants. These psychosocial interventions
included group cognitive behavioural therapy (CBT) (*Evins
2001; *Evins 2005; *Evins 2007); group therapy for motivational
enhancement, psychoeducation and relapse prevention (*George
2002); group behavioural therapy (*George 2008); smoking
cessation educational classes along with discussions with health
educators (^Horst 2005); and group therapy using the American
Cancer Society Fresh Start Programme (*Weiner 2007). The
duration of drug treatment varied from seven hours (+Hartman
1991) to six months (^Horst 2005).
Two trials predominantly examined the eFect of non-
pharmacological interventions. +Steinberg 2003 examined the
eFect of a single session of motivational interview and
compared this with didactic psychoeducation and minimal
control intervention. *George 2000 compared the American Lung
Association programme in a group setting with a specialised group
therapy designed for schizophrenia which had more focus on
motivational enhancement, psychoeducation, social skills training
and relapse prevention strategy; participants in both groups also
received TNP.
Two other trials investigated the combined eFect of
pharmacological and psychosocial interventions. In *Baker
2006, a combination of individually administered motivational
interviewing and CBT and TNP was compared with routine care. In
a three arm study, *Gallagher 2007 compared CR using money, with
and without additional TNP, and a self quit control without TNP.
Outcomes
Abstinence was defined and measured in 11 trials (*George 2000;
*Evins 2001; *George 2002; *Evins 2005; *Baker 2006; *Evins 2007;
*Gallagher 2007; *Weiner 2007; *Williams 2007; *George 2008;
*Li 2009). Two of these studies did not explicitly report whether
participants expressed any interest in quitting smoking and we
were not able to clarify this with the authors (*Li 2009; *Weiner
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2007). Three trials did not report any continuation of follow up
beyond the end of the intervention; *Williams 2007 and *Li 2009
reported abstinence at eight weeks; *Weiner 2007 aJer 14 weeks.
The other eight studies provided results aJer longer follow up, of at
least six months aJer the start of treatment. All trials except *Li 2009
validated abstinence biochemically. One study reported the rate of
relapse to smoking aJer abstinence (^Horst 2005).
Four trials only reported smoking reduction as the main outcome
measure (+Hartman 1991; +Dalack 1999; +Steinberg 2003; +Fatemi
2005). Most of the studies which measured smoking abstinence
also reported some measures of smoking reduction. Self-report
of reduction in CPD was commonly reported as a measure of
reduction (+Hartman 1991; +Dalack 1999; *Evins 2001; *George
2002; +Steinberg 2003; *Evins 2005; +Fatemi 2005; *Baker 2006;
*Evins 2007; *Gallagher 2007; *Li 2009). These outcomes were
reported aJer a range of follow-up periods which varied from two
days (+Hartman 1991) to 12 months (*Baker 2006). Expired CO level
reduction was also frequently reported as an outcome measure
of smoking reduction (+Dalack 1999; *George 2000; *George
2002; +Steinberg 2003; *Evins 2005; ^Horst 2005; *Gallagher
2007; *Weiner 2007). Other measures of smoking reduction
included plasma cotinine level (*Evins 2001), scale measure of
nicotine dependence (e.g. FTND) (+Fatemi 2005; +Steinberg 2003;
*Gallagher 2007; *Weiner 2007; *Li 2009), urine cotinine level
(+Fatemi 2005; *Weiner 2007) and salivary cotinine level (*Gallagher
2007).
Ten studies reported measures of mental state of the participants
(+Dalack 1999;*George 2000; *Evins 2001; *George 2002; *Evins
2005; +Fatemi 2005; *Baker 2006; *Evins 2007; *George 2008; *Li
2009).
2. Trials of interventions with primary aim other than smoking
cessation, reduction or relapse prevention
Five trials reported outcomes of smoking behaviour change, but
were not originally designed to investigate smoking cessation or
reduction (McEvoy 1995; de Leon 2005b; Kelly 2008; Weinberger
2008; Sacco 2009). One study only included participants with
schizoaFective disorder, bipolar type (Weinberger 2008). Three
studies included non-smokers as participants and performed
separate analyses for those who smoked, in relation to their
smoking behaviours (de Leon 2005b; Kelly 2008; Weinberger
2008). Two trials investigated the eFect of clozapine in patients
with treatment resistant schizophrenia ( McEvoy 1995; de Leon
2005b). Other interventions included galantamine (Kelly 2008),
atomoxetine (Sacco 2009) and topiramate (Weinberger 2008). None
of these five trials included smoking abstinence as an outcome, but
used various methods to measure smoking reduction.
Risk of bias in included studies
1. Trials of interventions for smoking cessation, reduction or
relapse prevention
We judged eight trials to have used an adequate method for
generating the randomization sequence (+Dalack 1999; *Evins
2001; +Steinberg 2003; *Evins 2005; ^Horst 2005; *Baker 2006;
*Evins 2007; *Gallagher 2007). Most of the other studies were
classified as unclear because there was no description of the
randomization process and we could not clarify details with the
investigators. We obtained additional information on *Li 2009 (see
details in Characteristics of included studies) and judged it as
having a high risk of bias (ROB).
We judged four studies to have used an adequate method of
allocation concealment (+Dalack 1999; *Evins 2001; *Evins 2005;
*Evins 2007). Other studies did not clearly report the method
of allocation concealment and we could not clarify this with
the investigators, so the risk of bias was unclear. From the
correspondence with *Li 2009, there was definitely no concealment
of allocation sequence and hence we judged the study as having a
high risk of bias. We had some clarification from *Gallagher 2007
regarding allocation concealment. In their study, allocation was not
done centrally and there was a possibility that research staF might
know which group the subsequent participant would be assigned
to. Hence, we judged that study as having a high risk of bias in
allocation concealment.
Adequate blinding to treatment allocation in assessment of
outcomes was observed in seven trials (+Hartman 1991; +Dalack
1999; *Evins 2001; *George 2002; *Evins 2005; +Fatemi 2005; *Evins
2007). Some studies reported double-blinding but their reports did
not explicitly state who was blinded and we were not able to clarify
with the investigators (*Weiner 2007; *Williams 2007; *George 2008;
*Li 2009). We judged that double-blinding implied that it was likely
participants and investigators were blinded, but declared all these
studies as having an unclear risk of bias; although it was likely that
the possible bias introduced to these studies was minimal. Some
studies were assessed to have inadequate blinding. Significant bias
could be introduced in these studies without adequate blinding,
as self-report measures (e.g. self-report reduction of cigarettes
used) and subjective assessment (e.g. assessment of psychiatric
symptoms) were used for outcome assessments. Two studies did
not report any blinding (*George 2000; *Gallagher 2007). Only the
outcome assessor was blinded in another two studies (+Steinberg
2003; *Baker 2006). ^Horst 2005 blinded participants but not the
outcome assessor.
There were wide-ranging variations in how missing outcome data
were handled among trials. We judged four studies as low risk
of bias secondary to incomplete outcome data (+Dalack 1999;
*George 2002; *Baker 2006; *Evins 2007 ). These studies included all
participants who were randomized and used proper ITT analysis.
Missing data were classified either as non-abstinent or as a failure
to achieve smoking reduction in these studies (*Baker 2006; *Evins
2007). Some trials used the "last observation carried forward"
approach to handle missing data (+Steinberg 2003; *Gallagher
2007). We had concern whether this approach was appropriate,
as those who lost to follow up may be more likely to relapse and
the "last observation carried forward" approach probably would
have overestimated the intervention eFect by assuming these
participants had maintained abstinence. Hence, we categorised
these trials as having a high risk of bias for incomplete outcome
data. In other trials, participants who were randomized were
excluded from the analysis for various other reasons. These reasons
included drop-out before start of intervention (*Evins 2001; *Evins
2005; *George 2008), the need for dose change for symptom
stabilization or side eFects of medications (*George 2000), stopping
the intervention during the trial (^Horst 2005; *Li 2009) and lost
to follow up (+Hartman 1991). We judged all these studies to have
a high risk of bias for incomplete outcome data. Three trials did
not clearly state how they handled missing outcome data and we
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classified them as having an unclear risk of bias (+Fatemi 2005;
*Weiner 2007; *Williams 2007).
Four studies did not report all outcome results as suggested in the
methods section or in their protocol, and these trials were classified
as having a high risk of selective reporting (+Dalack 1999; +Fatemi
2005; *Gallagher 2007; *Weiner 2007).
There were large diFerences in contact time between the
intervention group and the control group in three out of the
four trials which examined the eFect of non-pharmacological
interventions. *Baker 2006 compared an intervention involving
eight hours of individual contact over eight weeks with routine
care, which had no extra contact time. *Gallagher 2007 compared
three groups; CR with TNP, CR only; and self quit without any
active intervention. The self quit group had only three visits but
the other two groups had 12 visits for each group. +Steinberg 2003
compared three groups: motivational interview for 40 minutes;
didactic psychoeducation for 40 minutes; and minimal intervention
for five minutes.
There were some other possible biases. Despite randomization,
two studies had statistically significant diFerences in some
characteristics between the intervention and the control groups
(*George 2000; *Evins 2005). In ^ Horst 2005,where the RCT followed
an earlier open label phase, the report did not clearly state whether
the two comparison groups were similar in terms of their baseline
characteristics. Two trials lacked biochemical validation of smoking
status (+Hartman 1991; *Li 2009). Two of the three cross-over
studies had a relatively short washout period: five days (+Dalack
1999) and one week (+Hartman 1991). In the other cross-over study
(+Fatemi 2005), individual data were not available in the report and
it was unclear whether paired analyses were used in the analysis. In
those studies which were reported either as 'letters to editors' or as
conference proceedings (*Weiner 2007; *Williams 2007), there was
insuFicient information to assess whether any other important bias
existed and we judged them as unclear.
2. Trials of interventions with primary aim other than smoking
cessation, reduction or relapse prevention
We could only judge one study to have a low risk of bias in sequence
generation and allocation concealment (Kelly 2008). Other trials
did not explicitly describe the way in which the randomization
sequence was generated and we could not clarify this with the
investigators, so the risk of bias in sequence generation and
allocation concealment was unclear. Two trials reported double-
blinding but their reports did not explicitly state who were blinded
and we were not able to clarify this with the investigators (McEvoy
1995; Sacco 2009). The study by de Leon 2005b excluded four
subjects from the analysis without stating the reason. Another
study used the last observation carried forward method for missing
data (Weinberger 2008). We judged these two trials as having a high
risk of bias for the incomplete outcome data.
In two studies, the results in the reports were subgroup analyses
of larger related trials and some people who smoked were not
included in the analysis (Kelly 2008; Weinberger 2008). The reason
for not including these people was uncertain and selection bias
might have been introduced. The study by de Leon 2005b reported
unequal numbers among the intervention groups and there was
no information as to whether these groups were comparable in
characteristics and in their baseline cotinine level. There was also
baseline diFerence between comparison groups in the study by
McEvoy 1995. As a result, we judged all these trials as having a high
risk for other bias.
E5ects of interventions
See: Summary of findings for the main comparison Applicability
in clinical practice - projected numbers of people with
schizophrenia per hundred patients treated with smoking
cessation therapies (smoking abstinence at the end of the trial and
at follow-up aJer 6 months); Summary of findings 2 Applicability
in clinical practice - smoking reduction at the end of the trial and at
follow-up aJer 6 months among people with schizophrenia treated
with smoking cessation therapies
Trials are grouped under the following categories: (1) trials in
which the primary aim was smoking abstinence; (2) trials in
which the primary aim was smoking reduction; (3) trials in
which the primary aim was relapse prevention; (4) trials of other
interventions which reported smoking outcomes. Within each
category, if appropriate, trials were grouped according the principal
intervention comparison in each study. For instance, if the main
comparison of a study was a drug therapy (even if there was
any additional psychosocial intervention to both treatment and
placebo group), the study was grouped under pharmacological
interventions. Similarly, if the main comparison of a study was a
psychosocial intervention (even if there was any additional drug
treatment to all the comparison groups), this was grouped under
non-pharmacological interventions.
1. Trials with a primary aim of smoking abstinence
1.1 Pharmacological intervention - Bupropion
Intervention rationale: Bupropion is an atypical antidepressant
with both dopaminergic and adrenergic actions. There is robust
evidence that bupropion is a safe and eFective treatment
for nicotine dependence in the general population (Hughes
2007). There is however a theoretical concern about the
safety of using bupropion in patients with schizophrenia, as
bupropion may precipitate or exacerbate psychosis because of
its pharmacodynamic and pharmacokinetic properties. Bupropion
and its metabolite inhibit the cytochrome P450 CYP2D6
isoenzyme, and co-administration of bupropion with drugs that
are metabolised by this isoenzyme (including antipsychotic
medications such as risperidone, haloperidol) may cause
significant drug interactions (GlaxoSmithKline 2008). This, as
well as bupropion’s dopaminergic action, may adversely aFect
the mental state of individuals with schizophrenia. In addition,
seizure is a recognised adverse eFect of bupropion in the general
population, with a rate of between 0.1% and 0.4% (GlaxoSmithKline
2008).
Abstinence outcomes
Seven trials with a total of 340 participants investigated bupropion
as an aid for smoking cessation. Five trials (*Evins 2001; *George
2002; *Evins 2005; *Evins 2007; *George 2008) had six-months
follow up from the start of bupropion treatment, recruited
participants who were interested in quitting smoking, and set a
target quit date. Neither of the shorter-term trials (*Weiner 2007; *Li
2009) reported whether participants had any interest in quitting. At
six-month follow up, participants who took bupropion were nearly
three times more likely to be abstinent compared to those allocated
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to placebo, with a lower confidence interval that just excluded one
(5 trials, N=214, RR 2.78, 95% CI 1.02 to 7.58, I2 = 0%; Analysis
1.1; Figure 2). There was no strong evidence for a diFerence in
relative eFect between the three trials using bupropion as the sole
pharmacotherapy and the two trials using bupropion as an adjunct
to TNP (*Evins 2007; *George 2008); confidence intervals were wide
in both subgroups. The number of successful quitters was small in
all studies. Two trials (*Evins 2001; *Evins 2007) reported data of
smoking cessation from follow up of longer than six months: In the
two-year follow up report for *Evins 2001, 4 of 18 participants were
abstinent including the only one subject who was abstinent at the
end of the trial. The investigators reported that three of the four
abstinent aJer two years received bupropion SR during the trial or
during the follow-up period and the fourth quit during an extended
medical hospitalisation. By the 12-month follow up for *Evins 2007,
two more intervention group participants had relapsed. Had the
outcome at this point been used in the meta-analysis the estimated
eFect would have been smaller and the confidence intervals for the
pooled estimate would have included one.
 
Figure 2.   Bupropion versus placebo: Abstinence at 6-month follow-up (primary outcome)
 
The eFect size was similar for the secondary outcome of abstinence
at the end of treatment, but the confidence intervals were narrower
reflecting the two additional trials and the larger number of
successful short term quitters (7 trials, N=340; RR 2.84, 95% CI
1.61 to 4.99, I2 = 0%; Analysis 1.2). Sensitivity analyses detected no
important diFerence in eFect from omitting any of the following;
one trial was reported only as a conference abstract (*Weiner 2007);
two trials in which the participants' interest in quitting smoking
were uncertain (*Weiner 2007; *Li 2009); or one trial using the lower
dose of 150 mg bupropion daily, compared with 300 mg daily in
other trials (*Evins 2001).
Mental state outcomes
All trials reported the eFect of bupropion on the mental state of
the participants. Compared with placebo, there was no evidence
that bupropion caused any significant deterioration of positive,
negative or depressive symptoms in patients with schizophrenia
during smoking cessation.   Two studies provided suFicient final
measurement data for estimation of change of positive symptoms
and one additional study also provided suFicient data to estimate
the eFect of bupropion on negative and depressive symptoms.
There was no evidence that bupropion, compared to control,
caused a significant diFerence in positive symptoms (2 trials, N=85;
SMD -0.24, 95% CI -0.66 to 0.19; I2 = 0%), negative symptoms (3
trials, N=136; SMD -0.12, 95% CI -0.46 to 0.22; I2 = 0%) or depressive
symptoms (3 trials, N=136; SMD -0.16, 95% CI -0.50 to 0.18; I2 =
0%) (Analysis 1.3; Figure 3).  Other trials also consistently reported
that there was no significant diFerence in these symptoms between
the bupropion group and the placebo group aJer bupropion
treatment, but without reporting full data (*Weiner 2007; *George
2008; *Li 2009). In another study, bupropion treatment was
associated with improvement in negative symptoms and greater
stability of psychotic and depressive symptoms, compared to the
placebo, during the quit attempt (*Evins 2001). Three studies
also reported the eFect of abstinence on the mental state of
the subjects and there were no eFects of smoking abstinence on
positive, negative or depressive symptoms (*Evins 2005; *Evins
2007; *George 2008).
 
Interventions for smoking cessation and reduction in individuals with schizophrenia (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
13
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 3.   Bupropion versus placebo: Mental state outcomes
 
Other adverse e5ects
Regarding other adverse eFects of bupropion, no trials reported
any seizures. The prevalence of dry mouth was significantly
higher in the bupropion group compared to the control group
in one study (p<0.05) (*George 2002).  The same research
group, in a second study, reported significant diFerences on
concentration, jitteriness, light-headedness, muscle stiFness and
frequent nocturnal awakening in the bupropion group (*George
2008).  Three patients out of 59 participants (two in the placebo
group and one in the bupropion group) had psychotic breakdown
during that trial, but the authors concluded this was unrelated
to bupropion.  *Li 2009 reported significantly higher prevalence
of insomnia, dry mouth and sweatiness in the bupropion group
compared to the control group. Two subjects from this trial had
recurrence of psychotic symptoms but the author did not report
which group these two subjects were allocated to. One participant
in *Evins 2005 randomized to bupropion had an allergic reaction to
the medication. Two participants in *Evins 2007 using bupropion
and TNP dropped out from the trial because of insomnia and
dizziness. One trial did not mention any adverse eFects in the
reports (*Weiner 2007) and the remaining trial reported “no serious
adverse events” (*Evins 2001).
Smoking reduction
Most trials also reported some outcome measures for smoking
reduction. However, the data reported for these outcome measures
were likely from the entire sample (i.e. including both participants
who successfully abstained from smoking and participants who
continued to smoke). Three trials reported data for smoking
reduction measured by expired CO level. At the end of treatment,
there was a significant reduction of expired CO level in the
bupropion group compared to the control group (3 trials, N=123;
MD -7.03ppm, 95% CI -11.38 to -2.67ppm, I2 = 0%; Analysis 1.4).
Two trials reported incomplete data for expired CO level and did
not contribute in the meta-analysis, but both favoured bupropion
at the end of the treatment (*Evins 2001; *Weiner 2007). At six
months aJer start of treatment, there was no significant diFerence
in expired CO level (3 trials, N=123; MD -5.55ppm, 95% CI -17.89
to 6.78ppm; Analysis 1.5) but there was substantial heterogeneity
among trials (I2 = 83%), largely due to one trial in which the average
CO level was higher in the bupropion group than the placebo group
(*Evins 2005).
Three trials provided data from the entire sample to contribute to
a meta-analysis for smoking reduction measured by CPD. At the
end of bupropion treatment, there was a significant reduction of
number of CPD in the bupropion group compared to controls (3
trials, N=184; MD -10.77, 95% CI -16.52 to -5.01, I2 = 40%; Analysis
1.6). One study reported a separate analysis for participants who
had not quit smoking; those who received bupropion had a
significant reduction in CPD compared to those received placebo
(*Evins 2005). Another trial which did not provide raw data for meta-
analysis also reported a significant reduction in self-reported CPD
in the bupropion group versus the placebo group (*George 2002). At
six months aJer start of bupropion, two studies provided suFicient
data for meta-analysis. At this point there was no significant
diFerence in the number of CPD between the bupropion group and
the placebo group (2 trials, N=104; MD 0.40, 95% CI -5.72 to 6.53, I2=
0%; Analysis 1.7).
1.2 Pharmacological intervention - Transdermal nicotine patch
(TNP)
One trial compared the use of high dose (42mg) TNP with regular
dose (21mg) TNP in 51 patients with schizophrenia who wanted
to quit smoking (*Williams 2007). There was no placebo control
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group. Seven-day point prevalence abstinence rates at eight weeks
were not significantly diFerent between the high dose group (32%)
and the regular dose group (23%). Survival analysis examining
time to first relapse back to smoking also did not diFer between
two groups. However, the author reported that tolerability and
compliance was good for both groups.
Two other studies examined the eFect of TNP together with non-
pharmacological interventions (*Baker 2006; *Gallagher 2007). In
*Gallagher 2007, the smoking abstinence rate at the end of the trial
(36 weeks) were significantly higher in participants who used TNP
when compared to those without TNP; both groups also received
money as CR. Results of these two studies were summarised in the
following section of "combined interventions".
1.3 Non-pharmacological intervention
American Lung Association (ALA) programme in group setting
versus specialised smoking cessation group therapy designed for
schizophrenia (both groups received TNP)
*George 2000 investigated the eFicacy of specialised smoking
cessation group therapy among patients with schizophrenia who
were interested in quitting. There was a borderline significant
diFerence in smoking abstinence rate at the end of the trial
(based on continuous abstinence in the last 4 weeks of treatment)
between the ALA programme group (23.5%) and the specialised
group therapy group (32.1%, p = 0.06). However, at the six-month
follow up, smoking abstinence rate was significantly higher in
the ALA programme group (17.6%) than the specialised group
therapy group (10.7%, p<0.03). There was no statistically significant
diFerence in the expired CO level between the two therapy groups
during the course of the trial. There were also no significant
diFerences in psychiatric symptoms or medication side eFects
between the ALA group and the specialised group therapy group.
The authors also performed a secondary analysis based on whether
the subject received atypical or typical antipsychotic medications.
Smoking abstinence rates at the end of the trial and at six-
month follow up were significantly higher in the group of patients
who receive atypical antipsychotic medications.There was also
a significant reduction in expired CO level with TNP in patients
treated with atypical antipsychotic medications, compared to
those treated with typical antipsychotics.
1.4 Combined interventions
Individual smoking cessation intervention (based on cognitive
behavioural therapy and motivational interview) and TNP versus
routine care
*Baker 2006 compared the eFect of individual smoking cessation
intervention (based on CBT and motivational interview) and TNP
with routine care in a group of patients with psychotic disorder of
mixed diagnoses. All the participants expressed interest in quitting
smoking. The authors provided a subgroup analysis of subjects
with diagnosis of schizophrenia and schizoaFective disorder
(N=169). There were no overall statistically significant diFerences
between the treatment group and the control group in either
continuous abstinence or point prevalence abstinence rate at three
months, six months and twelve months aJer the initial assessment
(the authors had set the threshold for statistical significance at
p<0.01 to control for multiple comparisons). In terms of smoking
reduction, there was a significant diFerence in smoking reduction
at three months aJer the initial assessment, with 42.5% of the
treatment group reducing their cigarette consumption by at least
50% relative to baseline; compared to only 15.7% of the control
group (odds ratio 3.96, 99% CI 1.53 to 10.23, p<0.001). However,
the diFerences in smoking reduction between the treatment group
and the control group were not statistically significant at the
subsequent follow up sessions at six months and at 12 months aJer
the initial assessment.
Contingent reinforcement using money versus contingent
reinforcement and TNP versus minimal intervention
*Gallagher 2007, evaluated the eFects of CR using money (with and
without additional TNP) compared with minimal intervention in a
group of patients with serious mental illnesses. We conducted a
subgroup analysis for participants with diagnosis of schizophrenia
or schizoaFective disorder (N=80). About 32.5% of participants
expressed interest in quitting smoking. The abstinence rates at
week 20 and at week 36 (the end of the trial) were significant higher
in CR with TNP group compared to the CR group without TNP
(week 20: 56.3% versus 27.8%; week 36: 50% versus 27.8%) and
also versus the minimal intervention group (week 20: 10%; week 36:
10%). There was also a significantly larger reduction in FTND scores
in the CR with TNP group at both week 24 and week 36, compared
to the CR group without TNP and the minimal intervention group.
The CR with TNP group had a significantly lower expired CO level at
both week 20 and week 36 compared to the minimal intervention
group. However, there was no significant diFerence in the expired
CO level at either week 20 or week 36 between the CR with TNP
group and the CR group. CPD was lower at week 36 in the CR with
TNP group compared to the minimal intervention group but there
was no statistically significant diFerence at week 20. There was no
significant diFerence in the number of CPD at either week 20 or
week 36 between the CR group and the minimal intervention group,
nor between the CR with TNP group and the CR group.
2. Trials with a primary aim of smoking reduction
2.1 Pharmacological intervention - Bupropion
+Fatemi 2005 investigated the eFicacy of bupropion for smoking
reduction among patients with schizophrenia, using a cross-over
study design. These participants were encouraged to reduce the
amount they smoked, rather than to quit entirely. The investigators
reported that at the end of the 21-day active bupropion phase,
participants showed a non-significant trend for reductions in
exhaled CO, urine cotinine and urine nicotine and metabolites, as
compared to the placebo phase. Their results also showed that
during the trial, bupropion did not exacerbate positive and negative
symptoms in these patients.
2.2 Pharmacological intervention - Transdermal nicotine patch
Two cross-over trials investigated the eFicacy of transdermal
nicotine patch (TNP) as a single pharmacotherapy for smoking
reduction in schizophrenia. +Dalack 1999 examined the eFect of
TNP on smoking reduction over 32 hours in 10 participants with
schizophrenia who did not express interest in quitting smoking.
The expired CO level and CPD were not significantly diFerent
when the subjects were using the TNP or the placebo. Subgroup
analysis suggested that the heaviest smokers (identified by placebo
phase nicotine plasma level or expired CO level above group
median, i.e. nicotine plasma level >20.4 ng/ml or expired CO level
>42.5 ppm) had a statistically significant decrease in expired CO
level of at least 20%. The author reported that although nicotine
levels increased with the TNP, there was no evidence of nicotine
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toxicity or significant side eFects. Psychiatric symptoms did not
diFer significantly between the TNP phase and the placebo phase.
However, there was a statistically significant increase in abnormal
involuntary movements with TNP plus smoking and six out 10
subjects had more abnormal involuntary movement when using
the TNP.
+Hartman 1991 investigated the eFect of TNP for seven hours
on smoking reduction in a group of 14 people who did not try
to stop smoking. We re-analysed the data for 10 patients with
schizophrenia and schizoaFective disorder. These patients smoked
significantly fewer cigarettes while receiving nicotine than while
receiving placebo (N=10, mean number of cigarettes with nicotine
= 10.5, mean number of cigarettes with placebo = 13.5, t = -3.21,
df = 9, p <0.05). There was no biochemical measurement in this
trial. The report also noted that only patients who smoked at least
12 cigarettes (approximately 1.8/hour) while wearing the placebo
patch achieved benefit from the nicotine patch. No participants
reported any diFerence in subjective experience while wearing the
two patches, nor did they or the observers notice any changes in
their mental status.
2.3 Non-pharmacological intervention
Single session motivational interviewing versus didactic
psychoeducation versus minimal intervention
+Steinberg 2003 did not detect a significant reduction in CPD or
changes in expired CO level among the three groups at one week
and at one month aJer the psychosocial intervention. However,
a greater proportion of participants receiving the motivational
interviewing intervention followed through on a referral for
tobacco dependence treatment within one week and one month
post intervention, although there was no statistically significant
diFerence among the groups in their motivation to quit smoking.
The participants of this trial showed diFerent levels of interest in
quitting smoking.
3. Trials with a primary aim of preventing relapse to smoking
Transdermal nicotine patch
^Horst 2005 reported the relapse rate of recent quitters with
schizophrenia who were randomized to either active or placebo
TNP for six months. Participants had quit smoking by the end of
an open label phase during which they had received group support
and TNP. A significantly higher proportion of those on placebo
(eight out of eight) compared with those on active TNP (three out of
nine) relapsed prior to completion of the six-month period (p<0.01).
There was no report of skin rash for any subjects. In addition, the
authors did not report any dropouts due to adverse events.
4. Trials of other interventions reporting smoking outcomes
Clozapine
Intervention rationale: Clozapine is an atypical antipsychotic
medication and it carries a significant risk of agranulocytosis and
seizure. Hence, it is reserved to be used in patients with treatment
resistant schizophrenia. Previous literature (mainly naturalistic
studies or case reports) has suggested that clozapine treatment
may be associated with a reduction of smoking in schizophrenia.
We identified two RCTs that examined the eFect of diFerent
doses or blood levels of clozapine on the mental state in patients
with treatment resistant schizophrenia. These two trials measured
smoking behaviours of the participants; it was uncertain whether
participants had any interest in quitting smoking. One trial
investigated the number of cigarettes used and expired CO level
in patients with diFerent blood levels of clozapine (McEvoy 1995).
Subjects with a therapeutic plasma level of clozapine (>200ng/
ml) showed a significant decline of number of cigarettes used and
expired CO level at a range of 25-35%. Patients treated at sub-
therapeutic clozapine plasma levels (50-150 ng/ml) did not show
any change with respect to these measures of smoking. However,
the author also suggested a cautious interpretation of the results,
as those patients assigned to the sub-therapeutic clozapine also
had lower CO levels at baseline.
de Leon 2005b used a number of diFerent ways to re-analyse
the data on smoking status from an RCT of diFerent doses of
clozapine for 16 weeks. They did not find any evidence in any
of their five diFerent analyses to support clozapine for reducing
smoking. However, the author suggested that their study could not
rule out a small decrease in smoking in some subjects, which did
not yield significant changes in total sample mean values.
Galantamine
Intervention rationale: Galantamine is an acetylcholinesterase
inhibitor. It has been used as a cognitive enhancing
medication for dementia. Recent literature suggests its eFect
of cognitive enhancement may extend to other mental illness
like schizophrenia. It also acts as a positive allosteric modulator
of nicotine acetylcholine receptors (nAchR) and some research
has suggested that drugs that modulate nAchR may help in the
management of nicotine dependence.
Kelly 2008 investigated the eFect of galantamine on cognitive
function among patients with schizophrenia. In a secondary
analysis of data from smokers, they did not detect any statistically
significant diFerence in expired CO level before and aJer 12-
week galantamine treatment between participants who received
galantamine and placebo. On the contrary, there was a significant
and moderate increase in the mean score of FTND in subjects
with galantamine compared to placebo (eFect size of 0.4). These
participants did not express interest in quitting smoking.
Atomoxetine
Intervention rationale: Atomoxetine is a norepinephrine
(noradrenaline) reuptake inhibitor and it is approved for the
treatment of attention deficit hyperactivity disorder (ADHD).
Atomoxetine is thought to increase extracellular levels of both
norepinephrine and dopamine in the prefrontal cortex and this
may help to improve the neurocognitive deficits in patients with
schizophrenia. Nicotine may improve selected cognitive deficits
in these patients and one of the theories for the high rates of
smoking in schizophrenia is that patients with schizophrenia may
remediate their neurocognitive deficits by smoking. Hence, there is
a suggestion that atomoxetine may help in nicotine dependence by
improving the cognitive function of patients with schizophrenia.
Sacco 2009 investigated the eFects of atomoxetine on
cognitive function and cigarette smoking among patients with
schizophrenia. They did not detect any statistically significant
changes in smoking behaviours as measured by cigarette
consumption or expired CO levels in smokers with schizophrenia
taking atomoxetine for two weeks, when compared to those who
took placebo. The authors did not report whether the participants
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had any interest in quitting smoking. Atomoxetine was well-
tolerated and there was no evidence of changes in positive or
negative symptoms during the trial.
Topiramate
Intervention rationale: Topiramate is a novel anticonvulsant which
may have clinical benefits as an adjunctive treatment for bipolar
disorder. It has been suggested that topiramate may help in treating
addictions including nicotine dependence due to its modulation
of dopaminergic activity in the cortico-mesolimbic axis through
actions on GABAergic and glutamatergic systems.
Weinberger 2008 was a secondary analysis of a trial of the eFicacy
of topiramate as a treatment for schizoaFective disorder (bipolar
type). The investigators did not detect any significant change
in the expired CO level in a subgroup of 24 smokers treated
with topiramate or placebo, for eight weeks. There were also no
significant diFerences in the reduction of psychiatric symptoms
between the topiramate and the placebo group.
D I S C U S S I O N
Summary of main results
Interventions used in trials to help smokers with schizophrenia to
stop or to reduce smoking are heterogeneous. Summary of findings
for the main comparison and Summary of findings 2 summarises
the main results of this review for the most important outcomes.
Smokers with schizophrenia who used bupropion to aid smoking
cessation had nearly three times higher likelihood of abstinence
at the end of the drug therapy, compared with those who did
not.   Although there were fewer trials with six-month or longer
follow up, the relative eFect on abstinence seemed to be sustained
at six months, and the results appeared consistent among trials.
However, the evidence of sustained abstinence was based on five
small trials from just two research groups.
At the end of treatment, smokers with schizophrenia who received
bupropion smoked about 11 fewer CPD, than those who did not
take bupropion. A reduction of expired CO level also occurred
in the bupropion group, when it was compared to the placebo
group. However, the reduction was not sustained at six months. The
findings for smoking reduction should be interpreted cautiously,
as these data included the entire sample which consisted of
participants who had successfully abstained from smoking, as
well as those who continued to smoke aJer bupropion. Hence,
the reduction could be due to smoking abstinence, rather than
reduction in those who did not manage to stop smoking.
There was no evidence from the meta-analysis to suggest
that smokers with schizophrenia had significant deterioration in
positive, negative or depressive symptoms of schizophrenia due
to bupropion.  Although some adverse eFects of treatment which
may be important to patients were noted, there were no significant
adverse clinical events such as seizure or suicide. However, the total
number of subjects on bupropion was small (N = 170), so there
was not adequate power to test diFerences in risk of low event
rates, such as seizure (risk of seizure for bupropion in the general
population is between 0.1% and 0.4%).
It was unclear whether TNP helped smoking cessation in this
group of patients, as it was tested only in a small number of
trials with small sample sizes. There was some indirect evidence
that the abstinence rate was higher in the group with contingency
reinforcement with TNP, compared to the group with contingency
reinforcement alone (*Gallagher 2007). Some studies showed that
TNP may reduce the number of CPD (+Hartman 1991) or the FTND
score (*Gallagher 2007) but the evidence available did not show
that TNP reduced the expired CO level (+Dalack 1999, *Gallagher
2007). One study showed that TNP may reduce the relapse rate of
smoking aJer smoking abstinence in schizophrenia. Higher doses
of TNP did not show any additional benefit in smoking abstinence
or preventing relapse aJer smoking cessation in schizophrenia.
From trials using interventions for reasons other than smoking
cessation, there were inconclusive findings that the antipsychotic
clozapine helped in smoking reduction in schizophrenia. There
was no evidence to support the use of galantamine, atomoxetine
or topiramate as an aid in smoking cessation or reduction in
individuals with schizophrenia.
Regarding non-pharmacological interventions, one trial showed
evidence to support the use of CR with money for smoking
cessation in schizophrenia. There was also some evidence that
CR with and without TNP significantly reduces the FTND scores,
expired CO level and CPD. However, there was no evidence
that CR produced sustained results for these outcomes in the
longer term. As the evidence only came from a single study,
these findings should be treated with caution. There was no
evidence that a single session of motivational interviewing reduced
smoking in patients with schizophrenia. There was no evidence that
specialised smoking cessation group therapy specifically designed
for patients with schizophrenia was more eFective for either
smoking cessation or reduction, when compared to a standard
smoking cessation programme.
There were design limitations in most of the included trials. For
example, most studies had small numbers of participants and only
a few studies had outcomes aJer at least the six-month follow
up. These factors have limited the validity and precision of the
evidence.
Overall completeness and applicability of evidence
In this review, the participants of the included studies were
recruited from in-patient units, the community, or from outpatient
psychiatric treatment sites. Hence, they represented a range of
patients with schizophrenia. The interest in quitting smoking
varied across sites and studies. As a result, there was significant
heterogeneity of the included trials. Because of this, we considered
it was only appropriate to perform a meta-analysis and report
the pooled estimate among studies which examined bupropion,
because these studies were relatively more homogenous.
Our review included both pharmacological and non-
pharmacological interventions. For medication treatments, the
U.S. Food and Drug Administration (FDA) has approved nicotine
replacement therapies (gum, patch, nasal spray, inhaler and
lozenge), bupropion, and varenicline as first-line medications for
the treatment of nicotine dependence in the general public. For
this review, we found several studies that examined the use of
nicotine patch and bupropion for smoking cessation and reduction
in schizophrenia. There are also a number of ongoing studies
which investigate the use of varenicline (Meszaros (NCT00727103);
Evins (NCT00621777); Pfizer (NCT00644969); Smith (NCT00802919);
Weiner (NCT00554840)) but no results from these studies are
Interventions for smoking cessation and reduction in individuals with schizophrenia (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
17
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
available at present . We did not find any studies that examined
the eFect of other forms of nicotine replacement, such as gum,
nasal spray, inhaler and lozenge in people with schizophrenia,
but there is an ongoing study which investigates the use of
nicotine nasal spray for smoking cessation in schizophrenia
(Williams (NCT01010477)). We also did not find any trials of other
medications that have been investigated for possible eFicacy
for smoking cessation in the general public, such as clonidine,
nortriptyline, selegiline and naltrexone. We also examined the
eFects of antipsychotics (in particular clozapine) in smoking
reduction in schizophrenia, as there have been a number of
reports about the possible link between antipsychotic use and
nicotine dependence in schizophrenia (Ereshefsky 1985; McEvoy
1995). In addition, smokers with schizophrenia may use nicotine
to improve their cognitive function (Adler 1998, Sacco 2004). Thus,
we found studies which examined the eFects of medications
such as galantamine and atomoxetine in smoking reduction in
individuals with schizophrenia. Finally, topiramate modulates
dopaminergic activity in the brain through its action on GABAergic
and glutamatergic systems and it has been suggested that
topiramate may have an eFect in addiction (Johnson 2005). We
identified one study which examined its eFects on smoking in
patients with schizoaFective disorder.
Previous reviews have shown that individual behavioural
counselling, group behavioural therapy and telephone counselling
were eFective interventions to help smokers in the general public
to quit smoking (Lancaster 2005a; Stead 2005; Stead 2006). Simple
advice from a physician and self-help material may also have some
eFect on increasing smoking cessation rate in the general public
(Lancaster 2005b; Stead 2008). The one study which examined
the eFect of individual smoking cessation based on CBT and
motivational interviewing among smokers with schizophrenia
did not show any benefit in increasing abstinence. In another
study, there was no evidence that single session motivational
interviewing reduced the severity of smoking. There was no study
comparing group therapy with individual therapy in schizophrenia.
There was no evidence to support specialised smoking cessation
group therapy designed for patients with schizophrenia as being
superior to non-specialised group therapy. We also did not find
any studies on the eFect of telephone counselling, simple advice
from a physician, or self-help interventions in smoking cessation or
reduction in schizophrenia. Interestingly, we found some evidence
to support the use of incentives to increase the rate of abstinence
and to reduce the severity of smoking in the group of patients with
schizophrenia at the end of the trial, but this study did not have any
longer term follow up aJer the 36-week trial and a previous review
has shown that incentives do not enhance long-term cessation
rates and early success may not be maintained when the rewards
are no longer oFered (Cahill 2008).
In this review, we reported smoking reduction as one of the
secondary outcomes. Smoking cessation is the recommended
method to reduce the harm of smoking to smokers (US Department
of Health and Human Services 2000). However, the majority of
smokers never quit smoking, even those in countries with the most
eFective cessation activities such as the United States (Giovino
2002; West 2006). As a result, smoking reduction has been proposed
as one of the non-cessation methods to reduce harm from tobacco.
There is evidence to support that smokers who are not interested
in quitting can make significant reductions in their smoking when
they receive appropriate treatment and these reductions can be
maintained over time (Hughes 2005). One of the concerns over
smoking reduction is that it may undermine smokers' motivation
to quit smoking, as they may see reduction as an easier alternative
to abstinence; and that reduction may be all they desire to, or
can, accomplish. Nevertheless, recent literature has shown that
smoking reduction actually increases the probability of future
cessation (Hughes 2006). Individuals with schizophrenia have
much lower smoking cessation rates compared with the general
population (de Leon 2005a) and smoking reduction may be able to
be a step for them toward cessation. We hypothesise that this step
toward accomplishing the diFicult task of smoking cessation might
increase their self-eFicacy and make subsequent success more
likely. Smoking reduction may also make it easier to quit smoking
by reducing the level of nicotine dependence, as dependence is a
major barrier to smoking cessation (Shadel 2000).
Most of the trials also provided some information about any
potential harmful eFects of interventions, in particular on the
mental state of the participants. Some medications for smoking
cessation are psychotropic themselves (e.g. bupropion) and it is
important to monitor whether these medications have a major
impact on mental stability in these patients. In addition, nicotine
withdrawal can cause changes in the mental state, including
depression and anxiety (Zwar 2007).
There is some literature reporting interventions which address
tobacco addiction at an organisation or system level (Lawn
2005; Shmueli 2008; Wye 2009). These interventions may include
training of staF to manage tobacco addiction among patients with
schizophrenia and changing the psychiatric facilities into smoke-
free settings (Ziedonis 2007). This is particularly important as a
number of countries including the UK and the USA have enforced
smoking bans in mental health units. However, we did not find any
RCTs for these interventions in our search.
Quality of the evidence
In this review, we found the largest amount of evidence for
bupropion, which included seven studies and a total of 340
participants in the meta-analysis. Even though the number
of studies was still relatively small, there was no significant
heterogeneity among these studies. The amount of evidence for
the other interventions including NRT, individual counselling and
group therapy was limited, even though there is good evidence
of their benefit in other populations of smokers. Hence, the lack
of eFicacy for treatments other than bupropion for patients with
schizophrenia is likely due to the lack of evidence, rather than
negative trials.
The main aim of some included studies was to examine the eFicacy
of an intervention for other purposes, rather than primarily for
smoking cessation or reduction (de Leon 2005b and McEvoy 1995
for clozapine; Kelly 2008 for galantamine; Weinberger 2008 for
topiramate; Sacco 2009 for atomoxetine). These trials all included
smokers who were not trying to quit and smoking status was a
secondary outcome; subgroup analyses were used to investigate
the eFects of the interventions for a group of smokers. In three
trials, some of the smokers were excluded from the subgroup
analyses without justification. As a result, the results of these
studies should be viewed with caution.
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Potential biases in the review process
This systematic review used comprehensive search strategies and
widely inclusive criteria.  This improved the chance of identifying all
relevant trials. Reports in any language and unpublished data such
as conference abstracts were obtained to reduce potential selection
and publication biases. We included outcomes at least six months
aJer the intervention and at the end of the intervention, so that
the immediate eFect and longer term sustained abstinence could
be compared.  Sensitivity analyses were performed in the meta-
analysis and the robustness of the findings was also evaluated.
There are two issues to consider in this review. Firstly, the number
of studies which were included in the meta-analysis for bupropion
is relatively small, so we did not use a funnel plot to examine
potential publication bias. We could not exclude the possibility
that studies with negative results and small sample size may not
have been published.  Publication bias may significantly distort
the results from the meta-analysis especially when the number of
studies is relatively small.  Secondly, the findings may not apply to
all smokers with schizophrenia, as some of the included trials (in
particular those which examine the eFect of bupropion) explicitly
excluded patients who had a diagnosis of both schizophrenia and a
co-morbid substance misuse other than nicotine.
There is more emphasis recently on the importance of evaluating
the potential harms associated with interventions in both clinical
trials and systematic review (Cuervo 2003; Tunis 2003). This review
also examines the eFect of diFerent interventions on the mental
state of smokers with schizophrenia as one of the outcome
measures. This allows us to answer the question whether diFerent
interventions can be safely used in patients with schizophrenia for
smoking cessation and reduction.
Agreements and disagreements with other studies or
reviews
In the Cochrane review of antidepressants for smoking cessation
in the general population, Hughes 2007 estimated that bupropion
approximately doubled the odds of quitting smoking aJer at
least six months, when used as the sole pharmacotherapy (OR
1.94, 95% CI 1.72 to 2.19, 31 trials, 9940 participants). It did not
detect a significant eFect from combining bupropion and NRT,
compared to NRT alone (OR 1.37, 95% CI 0.65 to 2.91, 4 trials,
990 participants) aJer six months. Although our pooled estimates
suggest that bupropion may have a significant beneficial eFect
on smoking abstinence in schizophrenia when we combine all the
trials together, neither the subgroup analysis for bupropion alone,
or bupropion and TNP, individually reached statistical significance.
The results of this review largely concur with treatment guidelines
which make some recommendations about treatment of nicotine
dependence in schizophrenia. The Clinical Practice Guideline
published by the United States Department of Health and Human
Services (Fiore 2008) suggests that bupropion and nicotine
replacement therapies may be eFective for treating smoking in
individuals with schizophrenia. Zwar 2007 also gives a similar
suggestion for individuals with schizophrenia in the non-systematic
reviewed Australian guidelines regarding pharmacotherapy of
tobacco addiction.
The Schizophrenia Patient Outcomes Research Team (PORT)
has also recently published some treatment recommendations
(Kreyenbuhl 2009). The team recommends that people with
schizophrenia who want to quit or reduce cigarette smoking should
be oFered treatment with bupropion SR, 150 mg twice daily, for 10
to 12 weeks, with or without NRT to achieve short-term abstinence.
They also suggest that this pharmacological treatment should
be accompanied by a smoking cessation education or support
group, although they do not think there is suFicient evidence to
recommend a particular psychosocial approach.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Based on the best currently available evidence, the results of
this systematic review support the eFectiveness of bupropion in
smoking cessation, as well as smoking reduction in patients with
schizophrenia. The strength of the evidence is relatively weak
with wide confidence intervals, especially for longer term benefit,
because of the small number of participants. There is no evidence
to support any significant deterioration of mental state secondary
to use of bupropion in schizophrenia. Bupropion use in individuals
with schizophrenia did not increase risk of seizure.
For other drug treatment (including NRT) and psychosocial
interventions, we did not find suFicient and convincing evidence in
this review to support use in clinical practice.
Implications for research
Evidence for the eFectiveness of interventions for smoking
cessation and reduction in schizophrenia is limited to a small
number of small studies without adequate power to detect
reasonable treatment eFect. Further trials with adequate sample
size would be informative. Moreover, the report for future studies
should include more detailed and specific information. Some of the
included reports do not specify whether subjects had the intention
to quit smoking and the intention to quit can significantly aFect the
abstinence rate. It will also be useful to be more explicit whether
the reduction rates in the reports for trials with a primary aim to
investigate smoking abstinence include the entire sample, or only
subjects who do not quit.
In addition, the following areas should be considered for future
research:
1. the eFectiveness of NRT for smoking cessation and reduction,
especially with forms other than nicotine patches;
2. the interaction of antipsychotic medication treatment, and
smoking behaviour and cessation in schizophrenia;
3. the eFectiveness of diFerent forms of psychosocial
interventions, and the essential component(s) for the
eFectiveness of the intervention;
4. any sustained eFect on smoking cessation and reduction in CR
and other treatments;
5. the level of concordance of treatment for smoking cessation
among patients with schizophrenia;
6. the eFect of interventions at systematic and policies level on
smoking behaviours in patients with schizophrenia;
7. how to integrate treatment for smoking cessation into routine
psychiatric care;
8. economic analysis to address the cost-eFectiveness of diFerent
interventions. This would allow the construction of a decision
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analysis algorithm, which would aid clinicians, patients and
policy-makers in making evidence-based treatment decisions.
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* Indicates the major publication for the study
 
C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods RCT, Australia. Subjects recruited in the community.
Participants 298 smokers (at least 15 CPD) with ICD-10 diagnosis of psychotic disorder. Subjects who were acutely
psychotic, had acquired cognitive impairment and any medical conditions that would preclude the use
of nicotine patch were excluded. 
All participants interested in quitting; TQD set at week 3. 
156 male, mean age of all 298: 37.2, average CPD 30. 
126 had a diagnosis of schizophrenia and 43 a diagnosis of schizoaffective disorder.
Interventions 1. Individually administered smoking cessation intervention (6 weekly sessions and 2 boosters at week
8 and 10, 1 hour each): based on motivational interviewing and cognitive behavioural therapy (CBT) +
Transdermal nicotine patch (TNP) (21 mg from week 3 to 8; 14 mg from week 9 to 10; 7 mg from week
11 to 12) 
2. Routine care 
Both groups received booklets regarding smoking cessation.
Outcomes Abstinence measured at 3 m, 6 m and 12 m by continuous abstinence (from TQD to point of assess-
ment) and point-prevalence abstinence (from 7 days before the point of assessment). Both were from
subjects' self-report and confirmed with expired CO level < 10 ppm. 
Reduction of smoking measured at 3 m, 6 m and 12 m by incidence of achieving at least 50% reduction
of daily consumption of cigarettes. 
Effects on mental state were measured by BPRS, BDI and STAI.
Source of funding National Health and Medical Research Council; Rotary; Community Health and Tuberculosis Australia.
TNP was provided free of charge by GlaxoSmithKline and self-help booklets were provided at a dis-
counted price by SANE Australia.
Primary aim of the study Smoking cessation
Notes Results in the current review only included subjects with diagnosis of schizophrenia or schizoaffective
disorder. Data supplied by authors.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk Subjects drew a sealed envelope from a set of envelopes in which there was
initially an equal distribution of the treatment or control allocations at each
site.
Allocation concealment? Unclear risk No description of allocation concealment in the reports.
*Baker 2006 
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Blinding? 
All outcomes
High risk Outcome assessors were blinded. However, the experimental design did not
allow participants to be blinded and self-report were used in both primary and
secondary outcome measures.
Incomplete outcome data
addressed? 
All outcomes
Low risk Missing data were classified either as non-abstinent or as a failure to achieve
smoking reduction.
Free of selective report-
ing?
Low risk  
Free of other bias? High risk The control group were not comparable to the smoking cessation intervention
group as they differed in terms of therapy time. In addition, bias may be intro-
duced in definition of abstinence; if the participant reported abstinence but
their expired CO level was greater than 10ppm, the participant was still classi-
fied as abstinent.
*Baker 2006  (Continued)
 
 
Methods RCT, USA. Subjects recruited from the community.
Participants 19 smokers (at least half pack of cigarettes per day) with DSM-IV diagnosis of schizophrenia. All subjects
were on stable dose of antipsychotic medications for at least 4 weeks. Patients with co-morbid sub-
stance abuse or bulimia, or with a history of seizure disorder or current major depressive episode were
excluded. 
All participants interested in quitting; TQD set between weeks 3 and 4. 
11 male; mean age 44.1; 16 Caucasian; average CPD 34. 
8 subjects were on clozapine and 7 on typical antipsychotic. Average length of illness 12 years.
Interventions 1. Bupropion 150mg/day for 12 weeks 
2. Placebo for 12 weeks 
Both groups received nine weekly 1-hour sessions of group CBT
Outcomes Abstinence measured by point prevalence at weeks 12 & 24 (self-report verified by expired CO level < 9
ppm or serum cotinine < 14 ng/ml). A follow-up study also reported abstinence after 2 years. 
Reduction of smoking measured by serum cotinine, and incidence of achieving a ≥ 50% reduction in
CPD verified with a 30% reduction of expired CO level. Measurements at baseline, week 12 and 24. 
Effects on mental state measured by BPRS, SANS and HAM-D. Parkinsonism symptoms measured by
SAS and AIMS.
Source of funding NIDA & NARSAD. GlaxoSmithKline provided medications including placebo.
Primary aim of the study Smoking cessation
Notes Two-year follow up data were also available.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk Allocation sequence was generated by a computer program.
Allocation concealment? Low risk Randomization was performed at the research pharmacy which was separated
from the main research personnel.
*Evins 2001 
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Blinding? 
All outcomes
Low risk Participants, outcome assessors and investigators were blinded.
Incomplete outcome data
addressed? 
All outcomes
High risk 1/19 dropped out prior to medication and was not included in the analysis.
Free of selective report-
ing?
Low risk  
Free of other bias? Low risk  
*Evins 2001  (Continued)
 
 
Methods RCT, USA. Subjects recruited from the community.
Participants 57 smokers (at least 10 CPD) with DSM-IV diagnosis of schizophrenia or schizoaffective disorder, de-
pressed type. All participants were on antipsychotic medication for more than 30 days and had stable
psychiatric symptoms. Patients with substance use disorder (other than nicotine or caffeine) within 6
months, or with a history of seizure disorder, bulimia, mania or current major depressive episode were
excluded. 
All participants interested in quitting; TQD set at week 3. 
39 male; mean age 45.7; average CPD 30. 
12 subjects were on clozapine, 5 on typical antipsychotic.
Interventions 1. Bupropion 300 mg/day for 12 weeks (150 mg/day for first week) 
2. Placebo for 12 weeks 
Both groups received twelve weekly 1-hour sessions of group CBT.
Outcomes Seven-day point prevalence and 4-week continuous abstinence at week 12 and week 24 (self report
verified by expired CO level < 9 ppm). 
Reduction of smoking measured by expired CO level and number of cigarettes smoked. Measurements
at baseline, week 12, 14, 18 and 24. 
Effects on mental state measured by PANSS, SANS, HAM-D and HAM-A. Parkinsonism symptoms mea-
sured by SAS and AIMS.
Source of funding NIDA & NARSAD. GlaxoSmithKline provided medications.
Primary aim of the study Smoking cessation
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk Allocation sequence was generated by a computer program.
Allocation concealment? Low risk Randomization was performed at the research pharmacy which was separated
from the main research personnel.
Blinding? 
All outcomes
Low risk Participants, outcome assessors and investigators were blinded.
*Evins 2005 
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Incomplete outcome data
addressed? 
All outcomes
High risk 4/57 drop-out prior to medication (not included in the analysis), 10/53 drop-
out at week 12, 9 more drop-outs at week 24. Subjects who were lost to follow
up were included in the analysis as smokers.
Free of selective report-
ing?
Low risk  
Free of other bias? High risk More clozapine-treated subjects were randomized to the placebo group (1/25
versus 11/28).
*Evins 2005  (Continued)
 
 
Methods RCT, USA. Subjects recruited from the community.
Participants 51 smokers (at least 10 CPD for past year) with DSM-IV diagnosis of schizophrenia. All participants were
on antipsychotic medication for more than 30 days and had stable psychiatric symptoms. Patients with
substance use disorder (other than nicotine or caffeine) within 6 months, or with a history of seizure
disorder, bulimia, mania or current major depressive episode were excluded. 
All participants interested in quitting; TQD set at week 4. 
Sex distribution uncertain; mean age 44.2; average CPD 26. 
16 subjects were on clozapine.
Interventions 1. Bupropion SR 300mg/day for 12 weeks. (150 mg/day for first 7 days) 
2. Placebo for 12 weeks 
Both groups received: (1) twelve weekly 1-hour sessions of group CBT; (2) nicotine patch (from week 4)
21mg/day for 4 weeks, then 14 mg/day for 2 weeks, 7 mg/day for 2 weeks + up to 18 mg per day nico-
tine gum as required.
Outcomes Continuous abstinence at week 8, 12, 24 & 52 (defined by meeting the seven-day point prevalence ab-
stinence by self report every assessment after target quit date at the time point , verified by expired CO
level ≤ 8 ppm). 
Reduction of smoking measured by number of cigarettes smoked. Measurement at baseline, week 12 &
24. 
Effects on mental state measured by PANSS, SANS, HAM-D and STAI. Parkinsonism symptoms mea-
sured by SAS and AIMS.
Source of funding Massachusetts Department of Mental Health Federal Block Grant. GlaxoSmithKline provided medica-
tions including placebo.
Primary aim of the study Smoking cessation
Notes 6 month abstinence used in meta-analysis for comparability with other trials. 2 participants in the in-
tervention group relapsed by 1 year
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk Allocation sequence was generated by a computer program.
Allocation concealment? Low risk Randomization was performed at the research pharmacy which was separated
from the main research personnel.
Blinding? Low risk Participants, investigators and outcome assessors were blinded.
*Evins 2007 
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All outcomes
Incomplete outcome data
addressed? 
All outcomes
Low risk 5/25 (bupropion) and 8/26 (control) lost in follow up. Dropouts were consid-
ered smokers.
Free of selective report-
ing?
Low risk  
Free of other bias? Low risk  
*Evins 2007  (Continued)
 
 
Methods RCT, USA. Subjects recruited from the community and study conducted in a clinic.
Participants 181 participants (60 subjects in each arm, 1 died shortly after enrolment because of lung cancer) with
DSM-IV axis I diagnosis of psychotic spectrum or affective disorders. At least 10 cigarettes per day and
smoked regularly for more than 3 years. CO level ≥ 10 ppm after at least 15 minutes smoke-free at base-
line visit. Subjects with co-morbid substance misuse disorder were not excluded. No TQD set. 
80 had a diagnosis of schizophrenia or schizoaffective disorder. 50 of these 80 were male; mean age
42.3; 71.2% White, 20% Hispanic, 8.8% Black; average CPD 29. 32.5% wanted to cut down or quit smok-
ing. 47.5% had co-morbid diagnosis of substance misuse. 40% had diagnosis of schizophrenia.
Interventions 1. Contingent Reinforcement (CR) with money for 36 weeks (up to 480 US dollars) if participants ab-
stained from smoking. Participants did not receive reinforcement at the visit if they relapsed but they
would be able to resume receiving reinforcement if they abstained again. 
2. CR with money for 36 weeks (as above) + TNP (dose varies from subjects) for first 16 weeks 
3. Self-quit (no active intervention - just attended assessment) 
Significant support was provided to ensure adherence for all three groups, including reminder phone
calls and outreach, provision of bus pass to attend appointments.
Outcomes Abstinence at week 20 and week 36 (defined as expired CO level ≤ 10 ppm or salivary cotinine level ≤ 15
ng/ml). 
Reduction of smoking was measured by expired CO level, Fagerstrom Test for Nicotine Dependence
(FTND) score, salivary cotinine level and number of CPD. Measurements were taken at baseline and var-
ious points including week 20 and week 36. 
Effects on mental state measured by Brief Symptoms Inventory.
Source of funding Arizona Disease Control Research Commission
Primary aim of the study Smoking cessation
Notes Results in the current review only included subjects with diagnosis of schizophrenia or schizoaffective
disorder.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk The sequence was generated by a computer random number generator.
Allocation concealment? High risk A list of random numbers was used to allocate the participants by the research
staF.
*Gallagher 2007 
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Blinding? 
All outcomes
High risk Participants, investigators and outcome assessors were not blinded for the al-
location of intervention group.
Incomplete outcome data
addressed? 
All outcomes
High risk 29 subjects were lost during follow up at week 20 and another 6 subjects were
lost at week 36. Intention-to-treat analyses were conducted where data from
the last observation of participants lost to follow up were used. However, we
do not think the "last observation carried forward" approach was appropriate
for missing data.
Free of selective report-
ing?
High risk Only a few outcome measures were reported in the report.
Free of other bias? High risk The interventions were not comparable: the self-quit group had only 3 visits,
compared to 12 visits in the other two groups.
*Gallagher 2007  (Continued)
 
 
Methods RCT, USA. Setting unclear.
Participants 45 smokers with DSM-IV diagnosis of schizophrenia or schizoaffective disorder. FTND score at least 5. 
All participants interested in quitting; TQD set at week 3. 
30 males; mean age 39.7; 28 participants were White, 13 Black, 4 Hispanic; average CPD 30. 
19 had a diagnosis of schizophrenia. Mean daily dose of antipsychotics (chlorpromazine equivalence)
612.3 mg. 18 subjects were on atypical antipsychotics.
Interventions 1. American Lung Association (ALA) programme weekly for 10 weeks (60 minutes each session): first 7
weeks behavioural group therapy + final 3 weeks supportive group counselling 
2. Specialised group therapy designed for schizophrenia, weekly for 10 weeks (60 minutes each ses-
sion): first 3 weeks motivational enhancement therapy + last 7 weeks psychoeducation, social skills
training and relapse prevention strategy 
Both groups also received TNP (21 mg/day for first 6 weeks then 14 mg/day for another 2 weeks and 7
mg/day for final 2 weeks)
Outcomes Abstinence at week 10 (end of therapy) and at 6 months follow up (defined as continuous abstinence
for last 4 weeks - by self report of cigarette use and verified by expired CO level <10 ppm) 
Reduction of smoking measured by expired CO level; measurements at baseline and weekly for 12
weeks. 
Effects on mental state measured by PANSS and BDI. Parkinsonism symptoms measured by Webster
Extrapyramidal symptoms scale and AIMS.
Source of funding NIMDA, NARSAD & VISN 1 Mental Illness Research Education and Clinical Centre grant from Department
of Veteran Affairs, USA
Primary aim of the study Smoking cessation
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Mentioned block randomization but unclear how the allocation sequence was
generated.
Allocation concealment? Unclear risk No description of allocation concealment in the reports.
*George 2000 
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Blinding? 
All outcomes
High risk Participants were not blinded and unclear whether investigators or outcome
assessors were blinded.
Incomplete outcome data
addressed? 
All outcomes
High risk Subjects who were lost follow up were counted as smokers (number of sub-
jects lost to follow up was not reported). However, subjects who required a
dose change for symptom stabilisation or antipsychotic side effects were ex-
cluded from the analysis.
Free of selective report-
ing?
Low risk  
Free of other bias? High risk Baseline difference between two groups: specialised group therapy had signif-
icantly more subjects with schizoaffective disorder and subjects in that group
also had a significantly lower negative syndrome score; the ALA group had sig-
nificantly more subjects prescribed atypical antipsychotics.
*George 2000  (Continued)
 
 
Methods RCT, USA. Subjects recruited from the community.
Participants 32 smokers with DSM-IV diagnosis of schizophrenia or schizoaffective disorder. All subjects were clini-
cally stable on psychotic or affective symptoms. They also fulfilled the following criteria: (1) FTND score
≥ 5; (2) expired CO level ≥10ppm; (3) plasma cotinine level ≥150ng/ml. Subjects were excluded if they
had (1) history of epilepsy or seizure; (2) history of alcohol or drug abuse 6 months before the study; (3)
a change of dose of antipsychotic for symptom control or side effect in the past 6 months. 
All participants interested in quitting; TQD set at week 3. 
18 males; mean age 43.2; 20 White, 11 Black; average CPD 24. 
20 had a diagnosis of schizophrenia. 22 were on atypical antipsychotics. Mean daily dose of antipsy-
chotics (chlorpromazine equivalence) 757 mg
Interventions 1. Bupropion 300 mg/day for 10 weeks (150 mg/day for first 3 days) 
2. Placebo for 10 weeks 
Both groups received ten, weekly, 1-hour sessions of group therapy for motivational enhancement,
psychoeducation and relapse prevention.
Outcomes Abstinence at week 10 and 6 month follow up (defined as seven-day point prevalence and verified by
expired CO level < 10ppm) 
Reduction of smoking measured by expired CO level and self-report number of cigarettes smoked. 
Effects on mental state measured by PANSS and BDI. Parkinsonism symptoms measured by Webster
Extrapyramidal symptoms scale and AIMS.
Source of funding NIMDA, NARSAD & VISN 1 Mental Illness Research Education and Clinical Centre grant from Department
of Veteran Affairs, USA
Primary aim of the study Smoking cessation
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk The method of allocation sequence generation was not described.
*George 2002 
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Allocation concealment? Unclear risk No description of allocation concealment in the reports
Blinding? 
All outcomes
Low risk Both participants and outcome assessors were blinded.
Incomplete outcome data
addressed? 
All outcomes
Low risk 2/16 (bupropion) and 5/16 (control) lost in follow up. Dropouts were consid-
ered smokers.
Free of selective report-
ing?
Low risk  
Free of other bias? Low risk  
*George 2002  (Continued)
 
 
Methods RCT, USA. Subjects recruited from the community.
Participants 59 smokers (at least 10 CPD and expired CO > 10 ppm) with DSM-IV diagnosis of schizophrenia or
schizoaffective disorder. All subjects were clinically stable and on a stable dose of antipsychotic for
at least 1 month before randomization. Subjects with alcohol or substance misuse or dependence 3
months before study were excluded. Subjects also did not have any history of seizure disorder. 
All participants interested in quitting; TQD set at day 15. 
35 males; mean age 40.3; 28 Caucasians, 26 African Americans, 4 Hispanics; average CPD 23. 
32 had a diagnosis of schizophrenia. 9 subjects were on clozapine and 13 subjects were on typical an-
tipsychotic.
Interventions 1. Bupropion 300 mg/day for 10 weeks (150 mg/day for first 3 days) 
2. Placebo for 10 weeks 
Both groups received ten weekly 50-minute sessions of group behavioural therapy and TNP (21 mg per
24 hours) from day 15 to day 70.
Outcomes Abstinence was measured by self report as seven-day point prevalence at day 70, continuous absti-
nence for last 4 weeks of trial (day 43 to day 70) and 6 months post target quit date. Abstinence was ver-
ified by expired CO level <10ppm. 
Reduction of smoking was not reported. 
Effects on mental state were measured by PANSS, BDI and HAM-D.
Source of funding NIDA & NARSAD
Primary aim of the study Smoking cessation
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk The method of allocation sequence generation was not described.
Allocation concealment? Unclear risk No description of allocation concealment in the reports.
Blinding? 
All outcomes
Unclear risk Reported double-blind but uncertain who were blinded.
*George 2008 
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Incomplete outcome data
addressed? 
All outcomes
High risk 1 subject did not receive treatment after randomization and was excluded in
the analysis. 6 subjects from the bupropion group and 10 from the placebo
group were lost to follow-up. Another 6 subjects from bupropion group and 12
subjects from the placebo group discontinued intervention. Subjects who dis-
continued intervention or were lost to follow-up were included in analysis as
smokers.
Free of selective report-
ing?
Low risk  
Free of other bias? Low risk  
*George 2008  (Continued)
 
 
Methods RCT, China. Subjects recruited from a psychiatric in-patient unit.
Participants 80 smokers with DSM-IV diagnosis of schizophrenia and nicotine dependence. All subjects smoked at
least 10 CPD for minimum of 1 year. Their BPRS scores were ≤ 35 and CGI ≤ 3. Subjects with history of
epilepsy, unstable physical problem, alcohol or other substance dependence and prominent psychotic
symptoms were excluded.
Subjects' interest in quitting smoking and whether a target quit date was set were not mentioned in the
report.
All subjects were men. Mean age 38.0. Average number of CPD 30 and average years of smoking 17.
Interventions 1. Bupropion 75 mg bd for 1 week then 150 mg bd for remaining 3 weeks 
2. Placebo for 4 weeks 
No other addition intervention for both groups.
Outcomes Abstinence was defined as self-report continuous abstinence for past weeks at week 1, 2, 4 and 8. There
was no biological verification. 
Reduction of smoking measured by reduction in CPD and reduction of scores on scale measure of nico-
tine dependence. 
Effects on mental state measured by BPRS.
Source of funding Not reported
Primary aim of the study Smoking cessation
Notes Article in Chinese.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
High risk The report mentioned the use of random number table. However, we have
contacted the investigators to clarify the exact method of sequence genera-
tion. They told us that they used a random number table from a statistics text-
book and five investigators were given copies of this random number table.
When a subject was included, the investigators selected a random number
from the table. From the description, our opinion was that the investigators
did not use the random number table properly.
Allocation concealment? High risk From our correspondence with the investigators as above, there was definitely
no concealment of allocation sequence.
*Li 2009 
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Blinding? 
All outcomes
Unclear risk Mentioned double-blind in the report but unclear who were blinded.
Incomplete outcome data
addressed? 
All outcomes
High risk 4/40 bupropion and 7/40 placebo dropped out within first 2 days because of
non-compliance. However, no intention-to-treat analysis was used.
Free of selective report-
ing?
Low risk  
Free of other bias? High risk No biochemical verification of smoking status.
*Li 2009  (Continued)
 
 
Methods RCT, USA. Subjects recruited from the community.
Participants 46 smokers (at least 10 CPD) with DSM-IV diagnosis of schizophrenia or schizoaffective disorder. All sub-
jects had a FTND score ≥4 and they did not have any change in their usual medication regime. Subjects
with current depressive episode, current substance misuse or seizure disorder were excluded. 
Interest in quitting smoking was uncertain. TQD set at 2 weeks after start of bupropion. 
38 males; mean age 48.7.
Interventions 1. Bupropion 300 mg/day for 12 weeks (week 2 to week 14) 
2. Placebo for 12 weeks 
Both groups received 9 weekly sessions of group therapy according to American Cancer Society Fresh
Start Programme.
Outcomes Abstinence defined as expired CO level <10ppm and measured as point prevalence every week till week
14. 
Reduction of smoking was measured by expired CO level, FTND score and urine cotinine level. Measure-
ments at baseline and weekly till week 14. 
Effects on mental state measured by BRPS and SANS.
Source of funding VA Capitol Network (VISN 5) Mental Illness Research, Education and Clinical Centre
Primary aim of the study Smoking cessation
Notes Conference proceeding only.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk The method of allocation sequence generation was not described.
Allocation concealment? Unclear risk No description of allocation concealment in the reports.
Blinding? 
All outcomes
Unclear risk Reported double-blind but uncertain who were blinded.
Incomplete outcome data
addressed? 
All outcomes
Unclear risk 2 subjects dropped out from each group prior to medication treatment. 5 sub-
jects in bupropion group and 2 in the placebo group dropped out because of
side effects. 1 participant from each group withdrew consent during trial. 1
subject in the placebo group no longer met inclusion criteria during trial. How-
*Weiner 2007 
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ever, the report did not mention how drop-outs and missing data were han-
dled.
Free of selective report-
ing?
High risk Only some of the outcome measures mentioned in the protocol were reported.
Free of other bias? Unclear risk Insufficient information to assess whether an important risk of bias exists.
*Weiner 2007  (Continued)
 
 
Methods RCT, USA. Subjects recruited from the community.
Participants 51 smokers with DSM-IV diagnosis of schizophrenia or schizoaffective disorder. All subjects were stable
on antipsychotic medications. Subjects who took bupropion or clonidine were excluded. 
All participants interested in quitting. No TQD set. 
Baseline characteristics not reported.
Interventions 1. TNP 42mg daily for 8 weeks 
2. TNP 21mg daily for 8 weeks 
No other additional intervention for all groups.
Outcomes Abstinence measured at week 8 by self report of seven-day point prevalence and verified by expired CO
< 8ppm. 
Reduction of smoking was not reported. 
Effects on mental state were not reported.
Source of funding NIDA, New Jersey Department of Health and Senior Services
Primary aim of the study Smoking cessation
Notes Conference proceeding only.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk The method of allocation sequence generation was not described.
Allocation concealment? Unclear risk No description of allocation concealment in the reports.
Blinding? 
All outcomes
Unclear risk Reported double-blind but uncertain who were blinded.
Incomplete outcome data
addressed? 
All outcomes
Unclear risk Unclear whether there was any drop-out and how missing data were handled.
Free of selective report-
ing?
Low risk According to protocol, only outcome measure was continuous abstinence
from smoking and it was reported in the conference proceeding.
Free of other bias? Unclear risk Insufficient information to assess whether an important risk of bias exists.
*Williams 2007 
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Methods Cross-over study, USA. Subjects recruited from the community but they stayed in hospital during study.
Participants 10 subjects with DSM-IV diagnosis of schizophrenia or schizoaffective disorder. Moderate to severe
nicotine addiction (≥20 cigarettes per day). No current non-nicotine substance use disorder (confirmed
by urine toxicology). Stable on antipsychotic medication for at least 3 months. 
Participants had not expressed interest in quitting smoking. No TQD set. 
All males; mean age 42.1; 8 Caucasian; average CPD 35; average number of years smoking 26. 
4 subjects on clozapine. 6 subjects with diagnosis of schizophrenia. Average length of illness 23 years.
Interventions Transdermal nicotine patch (TNP) (22mg per 24 hours) versus placebo patch for 32 hours (Day 1 and
Day 2). Washout period for the next 5 days. Cross-over to the other intervention for 32 hours. 
No other addition intervention for both groups.
Outcomes Abstinence was not defined or measured. 
Reduction of smoking was measured by number of cigarettes smoked during the hospital stay and ex-
pired CO level. Measurements taken at baseline, the end of Day 1 and Day 2 (both weeks). 
Effects on mental state measured by BPRS, SANS, HAM-D. Parkinsonism symptoms measured by SAS
and AIMS.
Source of funding Research Advisory Group, Department of Veterans Affairs
Primary aim of the study Smoking reduction
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk A random number generator was used to generate sequence.
Allocation concealment? Low risk Allocation was performed centrally at pharmacy.
Blinding? 
All outcomes
Low risk Both participants and the outcome assessors were blinded to the allocation.
Incomplete outcome data
addressed? 
All outcomes
Low risk All subjects were included in data analysis.
Free of selective report-
ing?
High risk Only some of the outcomes were reported in the reports.
Free of other bias? High risk Cross-over study with short washout period.
+Dalack 1999 
 
 
Methods Cross-over study, USA. Subjects recruited from the community.
Participants 10 smokers with DSM-IV diagnosis of schizophrenia or schizoaffective disorder. 
Subjects encouraged to reduce their smoking, rather than to quit. No TQD set. 
Demographics for smokers were not reported.
Interventions Bupropion (dose uncertain) vs. placebo for 21 days. Washout period for 1 week afterwards. Cross-over
to the other intervention for another 21 days. 
+Fatemi 2005 
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No other addition intervention for both groups.
Outcomes Abstinence was not defined or measured. 
Reduction of smoking measured by number of cigarettes smoked, expired CO level, FTND, urine coti-
nine, urine nicotine and metabolites. Measurements taken at baseline and at the end of 21 days (for
both interventions). 
Effects on mental state measured by BPRS, PANSS, SAPS, SANS, HAM-D and BDI. Parkinsonism symp-
toms measured by SAS and AIMS.
Source of funding NIH
Primary aim of the study Smoking reduction
Notes The report is a letter to the editors.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk The method of allocation sequence generation was not described.
Allocation concealment? Unclear risk No description of allocation concealment in the reports
Blinding? 
All outcomes
Low risk Participants and investigators were blinded to intervention allocation.
Incomplete outcome data
addressed? 
All outcomes
Unclear risk One subject withdrew from the study and unclear whether this participant was
included in the analysis or not.
Free of selective report-
ing?
High risk Only the results of some of the outcome measures were reported.
Free of other bias? High risk Cross-over design but uncertain about whether paired analyses were used or
not. First period data were not available.
+Fatemi 2005  (Continued)
 
 
Methods Cross-over study, USA. Subjects were recruited from both inpatients and outpatients.
Participants 14 smokers with mixed psychiatric diagnoses and smoked at least 10 cigarettes daily. Subjects did not
have any other current substance use. 
Participants were not interested in quitting and no TQD was set. 
All males; mean age 40.9; 4 White, 7 Black, 2 Asian, 1 Hispanic. Average CPD 23. Average years of smok-
ing - 19. 
8 had a diagnosis of schizophrenia and 2 a diagnosis of schizoaffective disorder.
Interventions Transdermal nicotine patch (TNP) (8mg) vs. placebo patch for 7 hours (Day 1). Subjects stayed for the
next 2 entire days in the clinic for observation of smoking behaviour (although unlimited amount of
subjects' preferred brand of cigarettes were only provided during the 7 hours on patch). Cross-over to
the other intervention one week later. 
No other additional intervention for both groups.
Outcomes Abstinence was not defined or measured. 
+Hartman 1991 
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Reduction of smoking measured by collection of cigarette butts in subjects' own container (collection
of cigarette butts was observed). 
Effects on mental state were not measured.
Source of funding Not reported
Primary aim of the study Smoking reduction
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk The method of allocation sequence generation was not described.
Allocation concealment? Unclear risk No description of allocation concealment in the reports.
Blinding? 
All outcomes
Low risk Participants, investigators and outcome assessors were blinded.
Incomplete outcome data
addressed? 
All outcomes
High risk 1 subject was lost in follow-up but reason uncertain.
Free of selective report-
ing?
Low risk  
Free of other bias? High risk No biological verification of smoking status. Cross-over design with short
washout period.
+Hartman 1991  (Continued)
 
 
Methods RCT, USA. Setting unclear.
Participants 78 smokers (at least 10 cigarettes per day) with diagnosis of schizophrenia or schizoaffective disorder.
53% of participants also had a history of substance use disorder. 
Interest in quitting smoking varied among individuals. No TQD set. 
53 males; mean age 43.8; 60 Caucasians, 11 African Americans, 4 Africans, 3 Hispanic, 1 Asian; average
CPD 27. 
40 had a diagnosis of schizophrenia. Average length of illness was 20.8 years.
Interventions 1. Motivational Interview for 40 minutes (a single session) 
2. Didactic psychoeducation based on ALA brochure for 40 minutes (a single session) 
3. Minimal control intervention for 5 minutes (a single session) 
No other additional intervention for all groups.
Outcomes Abstinence not defined or measured. 
Reduction of smoking measured by number of cigarettes smoked, expired CO level and FTND scores.
Measurements taken at baseline, one week and one month after intervention. 
Effects on mental state not measured.
Source of funding National Cancer Institute Grant, NIDA and Centre for Substance Abuse Treatment Grant.
Primary aim of the study Smoking reduction
+Steinberg 2003 
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Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk Mentioned randomization in a ratio of 5:5:2 and the allocation sequence was
generated by computer.
Allocation concealment? Unclear risk No description of allocation concealment in the reports
Blinding? 
All outcomes
High risk Participants were not blinded. Outcome assessors were blinded to the partici-
pant group assignment.
Incomplete outcome data
addressed? 
All outcomes
High risk 3 subjects lost follow-up (2 from motivational interview group and 1 from psy-
choeducation group). Data were carried forward to replace missing values.
However, we do not think the "last observation carried forward" approach was
appropriate for missing data.
Free of selective report-
ing?
Low risk  
Free of other bias? High risk The minimal control intervention group was not comparable to the other two
interventions.
+Steinberg 2003  (Continued)
 
 
Methods Open-label phase study followed by RCT, USA. Subjects recruited from the community.
Participants 50 smokers with diagnosis of schizophrenia or schizoaffective disorder entered the open label phase.
They had stable symptoms for the last 2 months and used tobacco daily. 
All participants interested in quitting; TQD set. 
18 subjects entered the RCT phase as they fulfilled the following criteria: (1) agreed to set a quit date
within 2 weeks; (2) reduced their tobacco use by 75% after 60 days from the start of the open-label
phase; (3) quit smoking 100% after 90 days from the start of the open-label phase. 
For all subjects in the open-label phase, 26 were men; mean age was 42.5; average pack-years 39.9.
Interventions 1. TNP (Nicoderm CQ) for 6 months (Dose ranged from 14 mg to 63 mg daily, according to subjects' coti-
nine saliva levels. The dose was fixed throughout 6 months) 
2. Placebo patch for 6 months. 
All participants received biweekly educational smoking cessation classes and motivational discussions
with health educator.
Outcomes Relapse to smoking - defined by expired CO level greater than 10 ppm for 2 consecutive weeks. 
Abstinence not defined or measured. 
Reduction of smoking measured by expired CO level. Measurements taken at baseline, every 2 weeks
and at the final session. 
Effects on mental state not measured.
Source of funding American Legacy Foundation & Via Christi Foundation. SmithKlineBeecham provided placebo patches.
Primary aim of the study Relapse prevention after smoking cessation
Notes Only the data from the RCT were included in this review.
^Horst 2005 
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Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk Coin flip by blinded third party.
Allocation concealment? Unclear risk No description of allocation concealment in the reports.
Blinding? 
All outcomes
High risk Only participants were blinded. Investigators and outcome assessors were un-
blinded.
Incomplete outcome data
addressed? 
All outcomes
High risk 1 subject was excluded in the analysis as he stopped using any patch during
RCT phase.
Free of selective report-
ing?
Low risk  
Free of other bias? Unclear risk Uncertain whether there were any baseline differences for the two groups in
the RCT phase
^Horst 2005  (Continued)
 
 
Methods RCT, USA. Subjects were in-patients and study was conducted in hospital setting.
Participants 50 participants with DSM-IIIR diagnosis of schizophrenia. All were treatment resistant (not responded
at least 3 antipsychotics - each antipsychotic was prescribed for at least 6 weeks and at CPZ equivalent
dose of above 1000 mg daily). CGI at least moderately ill and BPRS-Anchored scores ≥ 45. 
Only 42 participants who were daily smokers were included in the analysis. Of these 42 subjects, 2 with-
drew before completing clozapine trial and another 2 did not provide sufficient cotinine measures. 
Interest in quitting smoking was uncertain. No target quit date set. 
Demographics for smokers not reported. Average CPD 19.
Interventions 1. Clozapine 100mg daily 
2. Clozapine 300mg daily 
3. Clozapine 600mg daily 
Duration of clozapine: 16 weeks. No other additional intervention for both groups. All subjects were
switched to haloperidol for 4 weeks and then had a washout period for 1 week before clozapine.
Outcomes Abstinence not defined or measured. 
Reduction of smoking measured by plasma cotinine; measurements at baseline and between 13th and
15th weeks. 
Effects on mental state measured by BPRS-Anchored, SANS and CGI.
Source of funding NIMH, NARSAD, Universidad Nacional (Medellin, Colombia). Novartis Research Institute provided free
medication.
Primary aim of the study Efftect of different doses of clozapine on mental state
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
de Leon 2005b 
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Adequate sequence gener-
ation?
Unclear risk The method of sequence generation was not described.
Allocation concealment? Unclear risk No description of allocation concealment in the reports.
Blinding? 
All outcomes
Low risk Participants and outcome assessors were blinded.
Incomplete outcome data
addressed? 
All outcomes
High risk 4 subjects excluded from the analysis although they were smokers.
Free of selective report-
ing?
Low risk  
Free of other bias? High risk Unequal numbers in the three intervention groups and uncertain whether
these three groups were comparable in characteristics and also baseline coti-
nine level.
de Leon 2005b  (Continued)
 
 
Methods RCT, USA. Subjects recruited from both inpatients and outpatients.
Participants 86 subjects with DSM-IV diagnosis of schizophrenia or schizoaffective disorder. All were treated by an-
tipsychotics except clozapine. Subjects were not on anticholingeric medications and with SAS score ≤4.
Subjects with DSM-IV diagnosis of alcohol or substance misuse or dependence (except nicotine) were
excluded.
73 subjects smoked (defined as baseline expired CO level ≥8 ppm). Only 41 subjects had at least 1 fol-
low-up measurement and were included in the analysis. Among these 41 subjects, 39 were men; mean
age 47.5; 14 White, 28 Black.
Participants not interested in quitting; no TQD.
Interventions 1. Galantamine for 12 weeks (up to 24 mg/day) 
2. Placebo for 12 weeks 
No other additional intervention for both groups.
Outcomes Abstinence not defined or measured. 
Reduction of smoking measured by expired CO level and FTND scores. Measurements taken at baseline
and every 2 weeks till week 12. 
Effects on mental state measured by BPRS, SANS and CGI. Parkinsonism symptoms measured by SAS
and AIMS.
Source of funding VA Capital Network (VISN 5) Mental Illness, Research, Education and Clinical Centre, Stanley Medical
Research Institute and NIMH. Ortho McNeil Neurologics supplied medications.
Primary aim of the study Effect of galantamine on cognitive function
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Kelly 2008 
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Adequate sequence gener-
ation?
Low risk Random sequence was generated by computer.
Allocation concealment? Low risk Allocation was performed centrally at the research pharmacy.
Blinding? 
All outcomes
Low risk Participants, outcome assessors and investigators were blinded.
Incomplete outcome data
addressed? 
All outcomes
Unclear risk Uncertain how missing data were handled.
Free of selective report-
ing?
Low risk  
Free of other bias? High risk Subgroup analysis of another trial with significant number of smokers not in-
cluded in the analysis.
Kelly 2008  (Continued)
 
 
Methods RCT, USA. Subjects were chronically hospitalised patients.
Participants 12 smokers with DSM-IIIR diagnosis of chronic schizophrenia. All subjects had persistent psychopathol-
ogy despite extended course of typical antipsychotics. 
Interest in quitting smoking was uncertain. No TQD set. 
8 males; mean age 34; average CPD 7. Average length of illness 16 years.
Interventions 1. Low clozapine (dose varied but plasma clozapine level 50-150ng/ml) for 12 weeks 
2. Medium clozapine (plasma level 200-300 ng/ml) for 12 weeks 
3. High clozapine (plasma level 350-450 ng/ml) for 12 weeks 
No other additional intervention for all groups.
Outcomes Abstinence was not defined or measured. 
Reduction of smoking measured by number of cigarettes smoked and expired CO level. Measurements
taken at baseline and week 12. 
Effects on mental state measured by BPRS and CGI.
Source of funding Not reported
Primary aim of the study Efftect of different doses of clozapine on mental state
Notes Subjects were allowed free access to cigarettes for 120 minutes only.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk The method of allocation sequence generation was not described.
Allocation concealment? Unclear risk No description of allocation concealment in the reports.
Blinding? 
All outcomes
Unclear risk Mentioned double-blind in the report but unclear who were blinded.
McEvoy 1995 
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Incomplete outcome data
addressed? 
All outcomes
Low risk All participants were included.
Free of selective report-
ing?
Low risk  
Free of other bias? High risk Potential baseline difference between groups: the low clozapine group had
lower baseline expired CO level.
McEvoy 1995  (Continued)
 
 
Methods RCT, conducted in the USA. Settings unclear.
Participants 12 smokers with DSM-IV diagnosis of schizophrenia. Demographics of participants unclear. Uncertain
whether subjects have interest in quitting smoking.
Interventions 1. Atomoxetine 40mg daily for 2 weeks 
2. Atomoxetine 80mg daily for 2 weeks 
3. Placebo for 2 weeks 
No other additional intervention for all groups.
Outcomes Abstinence not defined or measured. 
Reduction of smoking measured by number of cigarettes smoked and expired CO level. Measurements
were taken at baseline, day 8 and day 15. 
Effects of mental state were measured by PANSS.
Source of funding NARSAD & NIDA.
Primary aim of the study Effect of atomoxetine on mental state
Notes The report is a letter to the editors.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk The method of sequence generation was not described.
Allocation concealment? Unclear risk No description of allocation concealment in the reports.
Blinding? 
All outcomes
Unclear risk Reported double-blind but uncertain who were blinded.
Incomplete outcome data
addressed? 
All outcomes
Unclear risk Unclear whether there was any drop-out and how they handled drop-outs.
Free of selective report-
ing?
High risk Only report part of the results.
Free of other bias? Unclear risk Insufficient information to assess whether an important risk of bias exists
Sacco 2009 
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Methods RCT, USA. Subjects recruited from both inpatients and outpatients.
Participants 48 subjects with DSM-IV TR diagnosis of schizoaffective disorder, bipolar type. All subjects had a PANSS
score at least 60 and a CGI score at least 4. Participants were on a stable dose of lithium and/or val-
proate for at least 2 weeks before the study. Subjects with alcohol or marijuana dependence or other
substance misuse were excluded. 
Subjects did not have an interest in quitting smoking; no TQD set. 
31 daily smokers but only 24 participants (daily smoker and baseline expired CO level ≥ 10 ppm) were
included in the data analysis. Among these 24 participants; 12 males; 13 Whites, 10 African Americans;
mean age uncertain; average CPD 20.
Interventions 1. Topiramate (dose variable from 100mg to 400mg daily) for 8 weeks (after titration of dose) 
2. Placebo for 8 weeks 
No other additional intervention for all groups.
Outcomes Abstinence not defined or measured. 
Reduction of smoking measured by expired CO level. Measurements at baseline, week 4 and week 8. 
Effects of mental state measured by PANSS, MADRS, YMRS and CGI.
Source of funding NIDA & Ortho McNeil Neurologics (funded the medications and study)
Primary aim of the study Effect of topiramate on mental state
Notes The report is a letter to the editors.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Mentioned randomization in a ratio of 2:1 (favouring topiramate) but unclear
how the allocation sequence was generated.
Allocation concealment? Unclear risk No description of allocation concealment in the reports.
Blinding? 
All outcomes
Low risk Participants and outcome assessors were blinded.
Incomplete outcome data
addressed? 
All outcomes
High risk Missing data were imputed with the last observation carried forward. We do
not think the "last observation carried forward" approach was appropriate for
missing data. The number of dropouts was also not reported for the smoking
analysis.
Free of selective report-
ing?
Low risk  
Free of other bias? High risk Only 24 participants were analysed although there were 31 smokers.
Weinberger 2008 
AIMS: Abnormal Involuntary Movement Scale
BDI: Beck Depression Inventory
BPRS: Brief Psychiatric Rating Scale
CBT: cognitive behavioural therapy
CGI: Clinical Global Impression
CPD: cigarettes per day
HAM-D: Hamilton Depression Rating Scale
m: month
PANSS: Positive and Negative Syndrome Scale
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SANS: Scale for the Assessment of Negative Symptoms
SAPS: Scale for the Assessment of Positive Symptoms
SAS: Simpson Agnus Scale
STAI: State and Trait Anxiety Inventory
TNP: transdermal nicotine patch
TQD: target quit date
YMRS: Young Mania Rating Scale
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Brown 2003 Subjects aged below 18
Kisely 2006 Before and after study without randomization
McEvoy 1999 Before and after study without randomization
McKee 2009 The primary purpose of the study was to utilize mecamylamine as a mechanistic probe because of
its ability to increase smoking behaviour.
Roll 1998 Before and after study without randomization
Tidey 2002 Before and after study without randomization
Weiner 2001 No comparison group
Wells 2003 No measures of cigarettes consumption or smoking status. Only reported measure for motivation
to quit smoking.
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Controlled trial, conducted in Taiwan. Subjects were recruited from a day-care ward in a psychi-
atric hospital.
Participants 65 subjects with DSM-IV diagnosis of schizophrenia or schizoaffective disorder. All subjects smoked
more than 20 cigarettes daily and are willing to stay for 60 minutes for participating in the smok-
ing cessation group. Subjects with acute confusion, violent behaviours or did not attend more than
half of the sessions were excluded from the study.
Interest in quitting smoking was uncertain. No target quit date set.
60 subjects were men. Mean age 40.1.
Interventions 1. Smoking cessation group programme (total 8 hourly sessions in 4 weeks), modified from the
American Lung Association 7-steps. The programme included providing information of smoking
cessation, enhancing motivation, discussions of strategy in smoking cessation and relapse pre-
vention.
2. Control group with no intervention.
No other addition intervention for all groups.
Outcomes Self-report seven-day point abstinence measured at one week after participating in the smoking
cessation programme (i.e. week 5) and week 8. No biochemical verification.
Reduction of smoking was not reported.
Chen 2002 
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Effects of mental state were not reported.
Notes Attempts through different means have been made to contact the authors to clarify method of ran-
domization (it mentions in the report that subjects were randomly assigned to the two groups.
However, the allocation was uneven: 23 in the experimental group and 42 in the control group). So
far, there is no response from the authors.
Chen 2002  (Continued)
 
 
Methods Controlled trial, conducted in Taiwan. Subjects were recruited from a day-care ward in a psychi-
atric hospital.
Participants 68 subjects with diagnosis of schizophrenia. All subjects smoked at least 15 cigarettes per day for
minimum of 1 year. Subjects with history of using NRT within 6 months before study enrolment and
any current use of other smoking cessation treatments were excluded.
Interest in quitting smoking was uncertain. No target quit date set.
61 participants were men. Mean age 38.6. Average number of CPD 23.
Interventions 1. TNP for 8 weeks (14mg daily for week 1 to 6; 7mg daily during week 7 and 8)
2. No intervention for control group
No other addition intervention for all groups.
Outcomes Abstinence was defined as expired CO level <10ppm and measured as self-reported continuous
prevalence at the end of TNP treatment (i.e. week 8) and 3-month follow-up.
Reduction of smoking was measured by expired CO level and FTND score. Measurements were tak-
en at baseline, weekly for first 4 weeks, week 8 and 3-month follow-up.
Effects on mental state were measured by BRPS and HAS.
Notes Attempts through different means have been made to contact the authors to clarify method of ran-
domization (it mentions in the report that subjects were randomly assigned to the two groups,
matched by the CO level. However, the allocation was uneven: 26 in the experimental group and 42
in the control group). So far, there is no response from the authors.
Chou 2004 
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Healthy lifestyle intervention for cardiovascular disease risk reduction among smokers with psy-
chotic disorders
Methods RCT. Study is conducted in Australia.
Participants Adult smokers (at least 15 cigarettes per day) with a diagnosis of a psychotic disorder or bipolar
disorder. All subjects take antipsychotic medication as prescribed for at least 2 months.
Exclusion criteria: (1) non-English speaking; (2) organic brain damage; (3) medical condition that
would preclude NRT; (4) actively suicidal or acutely unwell.
Interventions 1. One initial 2-hour session of feedback + individual sessions of Motivational Interviewing and Cog-
nitive-behavioural therapy (MICBT), as well as Contingency Management (CM) with nicotine re-
Baker(ACTRN1260900103927) 
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placement therapy (NRT) [7 weekly sessions then 3 fortnightly sessions then 6 monthly sessions]
+ one final session
2. One initial 2-hour session of feedback + brief telephone and face contact + NRT
Outcomes Continuous and point prevalence of abstinence (confirmed by expired CO level} and self reported
number of cigarettes per day at week 15 and 12 months after initial assessment
Starting date July 2009
Contact information Amanda Baker (amanda.bake@newcastle.edu.au)
Notes Includes subjects with mental illness other than schizophrenia
Baker(ACTRN1260900103927)  (Continued)
 
 
Trial name or title A study of Varenicline for Prevention of Relapse to Smoking in Patients with Schizophrenia (SCRP)
Methods RCT. Study is conducted at multi-sites in Massachusetts, Michigan and New Hampshire, USA.
Participants Adult smokers (at least 10 cigarettes per day and expired CO level > 9ppm) with DSM-IV diagnosis
of schizophrenia or schizoaffective disorder. All subjects are willing to quit smoking and set a quit
date within 2 to 3 weeks.
Exclusion criteria: (1) diagnosis of dementia, neurodegenerative disease or organic mental disor-
der; (2) substance use disorder other than nicotine or caffeine in the last 6 months; (3) major de-
pressive disorder within the last 6 months; (4) serious unstable medical illness; (5) elevated liver
function tests over twice normal; (6) estimated creatinine clearance <40ml/min; (7) use other to-
bacco products apart from cigarettes (e.g. cigar, pipe); (8) current suicidal or homicidal ideation.
Interventions 1. Varenicline (1mg twice daily) for 12 weeks
2. Placebo for 12 weeks
Both groups also receive 13-session weekly CBT programme for smoking cessation.
Those subjects who have been abstinent for more than 2 weeks at the last 4 weeks of 12-week
treatment will enter a 40-week relapse prevention programme. They will again be randomized to
receive Varenicline or placebo in addition to CBT for relapse prevention.
Outcomes Abstinence is measured by the seven-day point prevalence abstinence rate at the end of the re-
lapse prevention phase at week 53.
Safety and tolerability of extended duration pharmacotherapy when added to antipsychotic med-
ications in schizophrenia patients who have recently quit smoking is also examined.
Starting date February 2008
Contact information Annie R. Shawn (ashawn@partners.org)
Notes Principal Investigator: A. Eden Evins, Massachusetts General Hospital
Evins (NCT00621777) 
 
 
Trial name or title Effects of rTMS on Smoking Cessation and Cognitive Outcomes in Outpatients with Schizophrenia
Treated With Transdermal Nicotine Patch
George (NCT00736710) 
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Methods RCT. Study is conducted at Centre for Addiction and Mental Health, Toronto, Ontoraio, Canada.
Participants Adult smokers (at least 10 cigarettes per day and a FTND score of at least 4) with DSM-IV diagnosis
of schizophrenia or schizoaffective disorder. All participants are willing to quit smoking in the next
30 days.
Exclusion criteria: (1) active alcohol or illicit drug abuse or dependence in the past 3 months; (2)
history of seizures, head trauma or space occupying lesions; (3) history of alcohol or illicit drug
abuse in the past 6 months; (4) intolerance of the nicotine patch; (5) evidence for psychiatric insta-
bility as judged by acute psychotic exacerbations, suicidal or homicidal ideation; (6) females who
are pregnant.
Interventions 1. Repetitive Trancranial Magnetic Stimulation (rTMS) - five times per week for 4 weeks
2. Sham rTMS
All participants also receive TNP (21mg/24 hour) and weekly group behavioural therapy (psychoe-
ducation, social skills training and relapse-prevention skills training) for smoking cession for 10
weeks.
Outcomes Smoking abstinence (7-day point prevalence) at week 10, as assessed by self-reported smoking ab-
stinence plus expired CO level <10ppm.
Reduction of smoking is measured by expired CO level.
Starting date December 2008
Contact information Tony George (tony_george@camh.net)
Notes  
George (NCT00736710)  (Continued)
 
 
Trial name or title Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia
Methods RCT. Study is conducted in Pennsylvania, USA. Both in-patients and out-patients are recruited.
Participants Adults smoker (at least one pack of cigarettes per day) with DSM-IV diagnosis of schizophrenia (all
subtype including schizoaffective disorder). The participants also show a less-than-optimal clinical
response to an adequate course of risperidone.
Exclusion criteria: (1) treatment refractory schizophrenia (as defined by treatment failure with 3 dif-
ferent antipsychotics of adequate duration in a sufficient dose); (2) significant extra-pyramidal side
effects or akathisia; (3) significant cardiac disease or unstable blood pressure; (4) history of seizures
or significant neurological disease; (5) active drug or alcohol addiction in the past 3 months; (6)
pregnancy or breastfeeding; (7) serious suicidal risk.
Interventions 1. Quetiapine (400mg to 800mg daily) for 12 weeks. Subjects start with Risperidone for 1 week and
switch to Queatiapine over 2 weeks before the 12-week trial.
2. Risperidone (4mg to 10mg daily) for 12 weeks
No other additional interventions for both groups.
Outcomes Abstinence is not measured.
Smoking reduction is measured by changes of FTND scores, expired CO level and blood levels of co-
tinine.
Josiassen (NCT00231101) 
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Mental state is monitored by PANSS, SANS and CGI.
Starting date January 2004
Contact information Richard C Josiassen (richardjosiassen@noyesfoundation.net)
Notes  
Josiassen (NCT00231101)  (Continued)
 
 
Trial name or title Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances
in Schizophrenia
Methods RCT. Study conducted in Beijing, China.
Participants Adults with diagnosis of schizophrenia or schizophreniform disorder and no previous history of
antipsychotic treatment. All participants resides in Beijing and their psychotic symptoms are less
than 60 months in duration and at least moderately severe.
Exclusion criteria: (1) other DSM-IV diagnosis apart from schizophrenia or schizophreniform dis-
order; (2) significant neurological disease; (3) significant and unstable medical conditions; (4)
Pregnancy or breastfeeding; (5) alcohol or illegal substance dependence; (6) use of other antipsy-
chotics, psychostimulants or antidepressants.
Interventions 1. Tropisetron (10mg daily) for 12 weeks
2. Placebo for 12 weeks
Both groups also receive Risperidone 6mg daily.
Outcomes Abstinence is not measured or defined.
Smoking reduction is measured by number of CPD. Uncertain whether there is any biochemical
verification.
Cognitive function and negative symptoms of schizophrenia is monitored.
Starting date November 2006
Contact information Thomas Kosten (kosten@bcm.edu)
Notes  
Kosten (NCT00435370) 
 
 
Trial name or title Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia - a Double
Blind, Placebo Controlled Trial
Methods RCT. Study is conducted in the USA. Subjects are recruited from the community.
Participants Adult smokers (at least 20 cigarettes per day over the 7 days prior to intake) with DSM-IV diagnosis
of schizophrenia or schizoaffective disorder. Subjects take antipsychotic medication for at least 4
weeks and with a current DSM-IV diagnosis of nicotine dependence and alcohol dependence. Sub-
jects also express desire to cut down or quit smoking and drinking.
Meszaros (NCT00727103) 
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Exclusion criteria: (1) unable to give informed consent; (2) currently receiving any pharmacologi-
cal smoking cessation treatment including bupropion; (3) currently taking naltrexone, Campral or
Anatabuse; (4) history of suicide attempt in the past year; (5) suicidal ideation at baseline; (6) fe-
male of childbearing potential without contraception; (7) pregnancy; (8) unstable medical or psy-
chiatric disorder; (9) positive urine drug screen for cocaine, opioids or amphetamine at baseline, or
current DSM-IV diagnosis of cocaine, opioid or cannabis dependence (1 month prior to enrolment).
Interventions 1. Varenicline 1mg bd for 8 weeks
2. Placebo (matched in appearance) for 8 weeks
Outcomes Smoking reduction is measured by expired CO level at the end of the treatment phase. Safety of
Varenicline including any adverse effects is recorded. Negative symptoms will be assessed with
PANSS.
Starting date June 2008
Contact information Ynesse Abdul-Malak (abdulmay@upstate.edu)
Notes Prinicipal Investigator: Zsusa Szombathyne Meszaros, SUNY Upstate Medical University, Depart-
ment of Psychiatry
Meszaros (NCT00727103)  (Continued)
 
 
Trial name or title Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder
Methods RCT. Study is conducted at different sites in USA and Canada.
Participants Adult smokers (at least 15 cigarettes per day during the past year with no period of abstinence
greater than 3 months in the past year) with DSM-IV diagnosis of schizophrenia or schizoaffective
disorder and judged to be stable. Participants are on psychiatric treatment for at least the past 6
months. They are motivated to stop smoking.
Exclusion criteria: (1) PANSS score at baseline > 70; (2) serious suicidal ideation or behaviour in the
past six months; (3) active suicidal ideation or behaviour; (4) taking bupropion.
Interventions 1. Varenicline 1mg twice daily for 12 weeks
2. Placebo for 12 weeks
Outcomes Abstience is defined as 7-day point prevalence of non-smoking at week 12 and week 24.
Smoking reduction is measured by proportion of subjects with at least 50% reduction from base-
line in CPD averaged over the past 7 days at week 12 and week 24. The change of CPD from baseline
at week 12 and week 24 is also monitored.
Mental state is measured with PANSS and CGI.
Starting date May 2008
Contact information Pfizer CT.gov call centre (1-800-718-1021)
Notes  
Pfizer (NCT00644969) 
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Trial name or title Contingency Management for Smoking Cessation Among Veterans With Schizophrenia or Other
Psychoses
Methods RCT. Study is conducted in the USA.
Participants Adults smokers (at least 5 or more cigarettes per day for at least 16 of the past 30 days prior to
study screening) with a diagnosis of schizophrenia or any other psychotic disorder (including bipo-
lar disorder with psychotic features, major depression with psychotic features). All subjects indi-
cate willingness to attend smoking cessation group therapy.
Exclusion criteria: (1) any current substance dependence disorder except nicotine dependence; (2)
imminent risk for suicide or violence; (3) severe psychiatric symptoms or psychosocial instability;
(4) gross cognitive impairment.
Interventions 1. Contingency Management (participants draw from a fishbowl to obtain tokens when they attend
a smoking cessation treatment session. The number of draws is based upon attendance at con-
secutive sessions. Tokens include messages of encouragement or canteen vouchers of varying
monetary value)
2. Reward as control (participants receive set reward [canteen voucher] for each week of smoking
cessation treatment they attend. The value of the reward will not change regardless of attendance
at consecutive sessions).
Outcomes Abstinence is measure by 7 and 30-day point prevalence and continuous abstinence from quit
date. Smoking reduction is measured by change in CPD.
Starting date July 2007
Contact information Kevin Wruck (kevin.wruck@va.gov)
Notes Principal Investigator: Andrew J. Saxon (VA Puget Sound Health Care System)
Saxon (NCT00508560) 
 
 
Trial name or title Varenicline for Cigarette Smoking in Schizophrenia - Efficacy and Predictors
Methods RCT. Study is conducted in New York, USA.
Participants Audlt smokers with diagnosis of schizophrenia or schizoaffective disorder. Participants are taking
antipsychotic medication.
Exclusion criteria: (1) significant cardiac disease or past history of stroke; (2) history of using vareni-
cline with serious side effects; (3) suicide attempt or serious suicidal ideation in the past year; (4)
pregnant or breastfeeding; (5) significant renal impairment; (6) baseline HDRS score > 20.
Interventions 1. Varenicline 1-2mg daily for 12 weeks
2. Placebo for 12 weeks
Outcomes Abstinence is not measured.
Smoking reduction is measured by cotinine level.
Mental state is monitored with PANSS and HDRS.
Starting date September 2008
Contact information James Cornwell (marcjfc@omh.state.ny.us)
Smith (NCT00802919) 
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Notes Principal Investigator: Robert C Smith
Smith (NCT00802919)  (Continued)
 
 
Trial name or title Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia
Methods RCT. Study is conducted in Rhode Island, USA.
Participants Adult smokers (20 to 50 cigarettes per day) with diagnosis of schizophrenia or schizoaffective dis-
order. Participants are clinically stable and they are on antipsychotic and antidepressant medica-
tions.
Exclusion criteria: (1) pregnancy or breastfeeding: (2) history of seizure; (3) use drugs that may in-
teract with bupropion; (4) positive urine drug screen or positive breath alcohol test.
Interventions 1. Bupropion (300mg daily for 3 weeks) with CR (giJ cards to local grocery stores when their cotinine
levels indicate that they have reduced their smoking)
2. Placebo with CR
3. Bupropion (300mg daily for 3 weeks) with non-contingent reinforcement (receive giJ cards re-
gardless of cotinine level)
4. Placebo with non-contingent reinforcement
Outcomes Abstinence is not measured.
Smoking reduction is measured by urinary cotinine level and CPD at week 3, as well as follow-up 2
and 4 weeks after the end of trial.
Starting date September 2003
Contact information Jennifer W. Tidey (jennifer_tidey@brown.edu)
Notes  
Tidey (NCT00136760) 
 
 
Trial name or title Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia
Methods RCT. Study is conducted in USA.
Participants Adults smokers (at least 10 cigarettes daily for one year and nicotine dependency score ≥4) with
DSM-IV diagnosis of schizophrenia or schizoaffective disorder. Participants have their psychiatric
medication regimen unchanged for at least 90 days and dosage unchanged for at least 30 days.
Exclusion criteria: (1) psychiatric hospitalisation in past 6 months; (2) meet criteria for current ma-
jor depressive disorder or score greater than 10 on the Calgary Depression Scale; (3) suicide or
homicide plan in the last 6 months; (4) life time history of suicide attempt; (5) diagnosis of schizo-
phrenia or schizoaffective disorder for less than 3 years; (6) current treatment with bupropion; (7)
DSM-IV diagnosis of alcohol or substance dependence (apart from nicotine) within last 6 months;
(8) DSM-IV diagnosis of alcohol or substance abuse (apart from nicotine) within 3 months; (9) Preg-
nancy or breastfeeding; (10) use of tobacco product other than cigarettes; (11) use of nicotine re-
placement; (12) unstable or serious medical condition in the last 6 months; (13) regular use of
cimetidine.
Interventions 1. Varenicline (1 mg twice daily) for 12 weeks
Weiner (NCT00554840) 
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2. Placebo for 12 weeks
Outcomes Abstinence is measured at point prevalence at week 12 and 4-week continuous abstinence at the
last four weeks of the treatment by self report and biochemical verification (expired CO level <
10ppm and urine cotinine measure < 30ng/ml).
Mental state is also monitored.
Starting date November 2007
Contact information Elaine Weiner (eweiner@mprc.umaryland.edu)
Notes  
Weiner (NCT00554840)  (Continued)
 
 
Trial name or title Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia
Methods RCT. Study is conducted in the USA.
Participants Adult smokers with DSM-IV diagnosis of schizophrenia. Participants smoke at least 10 cigarettes
per day and have an expired CO level >9ppm. They are also motivated to quit smoking and on atyp-
ical antipsychotic medication for at least one month.
Exclusion criteria: (1) current suicidal risk; (2) psychiatric hospitalization in the last 30 days; (3) un-
able to read or understand questionnaires in English; (4) pregnant or lactating; (5) regular use of
non-cigarette forms of tobacco; (6) Mini-mental state examination score <22
Interventions 1. Nicotine Nasal Spray (minimum 8 doses of nasal spray per day; maximum 5 doses per hour, no
more than 40 doses per day) for 20 weeks
2. Placebo for 20 weeks
Both group will also receive behavioural intervention
Outcomes Abstinence is defined as self report of no tobacco use for 4 weeks, confirmed by exhaled CO level
<10ppm during these period. Abstience will be assessed at week 5, week 12, week 20, week 26 and
week 52.
Starting date August 2009
Contact information Jill M Williams, University of Medicine and Dentistry, New Jersey
Notes  
Williams (NCT01010477) 
 
 
Trial name or title Treating Addiction to Nicotine in Schizophrenia (TANS) NIDA Stage I Behavioral Therapy Develop-
ment Study
Methods RCT in second phase. Study is conducted in the USA.
Participants Smokers with schizophrenia. Details unclear but participants are motivated to quit smoking. Quit
date is set at week 5.
Ziedonis 
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Interventions 1. High Intensity Treament named TANS (24 sessions in 26 weeks). TANS is comprised of first 4 ses-
sions of engagement, another 10 sessions of achieving abstinence and final 10 sessions of relapse
prevention. The treatment integrates and modifies Motivational Enhancement Therapy, Relapse
Prevention, specific tobacco dependence treatments and Social Skills Training into a single ther-
apy.
2. Moderate Intentsity Treatment called Medication Management (9 sessions in 26 weeks)
Both groups also receive 20 weeks of nicotine patch.
Outcomes Abstinence is measured but details not certain.
Reduction is measured with expired CO level, number of CPD and FTND score.
Starting date 2006
Contact information Douglas Ziedonis, Department of Psychiatry, University of Massachusetts Medical School
Notes  
Ziedonis  (Continued)
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Comparison 1.   Bupropion versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Abstinence at 6-month follow-up
(primary outcome)
5 214 Risk Ratio (M-H, Random, 95% CI) 2.78 [1.02, 7.58]
1.1 Bupropion versus Placebo 3 104 Risk Ratio (M-H, Random, 95% CI) 2.19 [0.50, 9.63]
1.2 Bupropion + TNP versus Placebo +
TNP
2 110 Risk Ratio (M-H, Random, 95% CI) 3.41 [0.87, 13.30]
2 Abstinence at end of treatment (sec-
ondary outcome)
7 340 Risk Ratio (M-H, Random, 95% CI) 2.84 [1.61, 4.99]
2.1 Bupropion + TNP vs. Placebo + TNP 2 110 Risk Ratio (M-H, Random, 95% CI) 2.92 [0.75, 11.33]
2.2 Bupropion vs. Placebo 5 230 Risk Ratio (M-H, Random, 95% CI) 3.21 [1.51, 6.81]
3 Mental state outcomes 3   Std. Mean Difference (IV, Random, 95%
CI)
Subtotals only
3.1 Positive symptoms at the end of
treatment (final measurements)
2 85 Std. Mean Difference (IV, Random, 95%
CI)
-0.24 [-0.66, 0.19]
3.2 Negative symptoms at the end of
treatment (final measurements)
3 136 Std. Mean Difference (IV, Random, 95%
CI)
-0.12 [-0.46, 0.22]
3.3 Depressive symptoms at the end of
treatment (final measurements)
3 136 Std. Mean Difference (IV, Random, 95%
CI)
-0.16 [-0.50, 0.18]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4 Reduction - Expired CO level at the
end of treatment (secondary outcome)
3 123 Mean Difference (IV, Random, 95% CI) -7.03 [-11.38, -2.67]
4.1 Studies using final measurements 2 104 Mean Difference (IV, Random, 95% CI) -6.10 [-10.71, -1.49]
4.2 Studies using change from baseline 1 19 Mean Difference (IV, Random, 95% CI) -14.8 [-28.15, -1.45]
5 Reduction - Expired CO level at 6-
month follow-up (secondary outcome)
3 123 Mean Difference (IV, Random, 95% CI) -5.55 [-17.89, 6.78]
5.1 Studies using final measurements 2 104 Mean Difference (IV, Random, 95% CI) -2.08 [-17.76, 13.59]
5.2 Studies using change from baseline 1 19 Mean Difference (IV, Random, 95% CI) -14.30 [-27.20,
-1.40]
6 Reduction - Change in number of
CPD from baseline at the end of treat-
ment (secondary outcome)
3 184 Mean Difference (IV, Random, 95% CI) -10.77 [-16.52,
-5.01]
7 Reduction - Change in number of
CPD from baseline at 6-month fol-
low-up (secondary outcome)
2 104 Mean Difference (IV, Random, 95% CI) 0.40 [-5.72, 6.53]
 
 
Analysis 1.1.   Comparison 1 Bupropion versus placebo,
Outcome 1 Abstinence at 6-month follow-up (primary outcome).
Study or subgroup Bupropion Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 Bupropion versus Placebo  
*Evins 2001 1/10 0/9 10.56% 2.73[0.12,59.57]
*Evins 2005 1/25 1/28 13.59% 1.12[0.07,16.98]
*George 2002 3/16 1/16 21.64% 3[0.35,25.87]
Subtotal (95% CI) 51 53 45.8% 2.19[0.5,9.63]
Total events: 5 (Bupropion), 2 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.34, df=2(P=0.85); I2=0%  
Test for overall effect: Z=1.04(P=0.3)  
   
1.1.2 Bupropion + TNP versus Placebo + TNP  
*George 2008 4/30 0/29 12.13% 8.71[0.49,154.89]
*Evins 2007 5/25 2/26 42.08% 2.6[0.55,12.19]
Subtotal (95% CI) 55 55 54.2% 3.41[0.87,13.3]
Total events: 9 (Bupropion), 2 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.56, df=1(P=0.46); I2=0%  
Test for overall effect: Z=1.76(P=0.08)  
   
Total (95% CI) 106 108 100% 2.78[1.02,7.58]
Total events: 14 (Bupropion), 4 (Placebo)  
Heterogeneity: Tau2=0; Chi2=1.08, df=4(P=0.9); I2=0%  
Test for overall effect: Z=2(P=0.05)  
Favours placebo 1000.01 100.1 1 Favours bupropion
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Study or subgroup Bupropion Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for subgroup differences: Not applicable  
Favours placebo 1000.01 100.1 1 Favours bupropion
 
 
Analysis 1.2.   Comparison 1 Bupropion versus placebo, Outcome
2 Abstinence at end of treatment (secondary outcome).
Study or subgroup Bupropion Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 Bupropion + TNP vs. Placebo + TNP  
*George 2008 8/30 1/29 7.86% 7.73[1.03,58.02]
*Evins 2007 9/25 5/26 35.7% 1.87[0.73,4.82]
Subtotal (95% CI) 55 55 43.55% 2.92[0.75,11.33]
Total events: 17 (Bupropion), 6 (Placebo)  
Heterogeneity: Tau2=0.46; Chi2=1.72, df=1(P=0.19); I2=41.86%  
Test for overall effect: Z=1.55(P=0.12)  
   
1.2.2 Bupropion vs. Placebo  
*Evins 2001 1/10 0/9 3.35% 2.73[0.12,59.57]
*Evins 2005 4/25 0/28 3.86% 10.04[0.57,177.65]
*George 2002 6/16 1/16 7.97% 6[0.81,44.35]
*Weiner 2007 5/24 3/22 18.61% 1.53[0.41,5.66]
*Li 2009 12/40 3/40 22.65% 4[1.22,13.11]
Subtotal (95% CI) 115 115 56.45% 3.21[1.51,6.81]
Total events: 28 (Bupropion), 7 (Placebo)  
Heterogeneity: Tau2=0; Chi2=2.43, df=4(P=0.66); I2=0%  
Test for overall effect: Z=3.04(P=0)  
   
Total (95% CI) 170 170 100% 2.84[1.61,4.99]
Total events: 45 (Bupropion), 13 (Placebo)  
Heterogeneity: Tau2=0; Chi2=4.4, df=6(P=0.62); I2=0%  
Test for overall effect: Z=3.62(P=0)  
Test for subgroup differences: Not applicable  
Favours placebo 1000.01 100.1 1 Favours bupropion
 
 
Analysis 1.3.   Comparison 1 Bupropion versus placebo, Outcome 3 Mental state outcomes.
Study or subgroup Experimental Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.3.1 Positive symptoms at the end of treatment (final measurements)  
*Evins 2005 25 8.2 (5.6) 28 10 (4.5) 61.91% -0.35[-0.89,0.2]
*George 2002 16 11.6 (3.9) 16 11.8 (3.3) 38.09% -0.05[-0.75,0.64]
Subtotal *** 41   44   100% -0.24[-0.66,0.19]
Heterogeneity: Tau2=0; Chi2=0.43, df=1(P=0.51); I2=0%  
Test for overall effect: Z=1.08(P=0.28)  
   
1.3.2 Negative symptoms at the end of treatment (final measurements)  
*Evins 2005 25 31.8 (12.1) 28 35.6 (20) 38.75% -0.23[-0.77,0.32]
Favours bupropion 10.5-1 -0.5 0 Favours control
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Study or subgroup Experimental Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
*Evins 2007 25 39 (16) 26 40 (16) 37.63% -0.06[-0.61,0.49]
*George 2002 16 10.7 (3) 16 10.8 (2.6) 23.63% -0.03[-0.73,0.66]
Subtotal *** 66   70   100% -0.12[-0.46,0.22]
Heterogeneity: Tau2=0; Chi2=0.25, df=2(P=0.88); I2=0%  
Test for overall effect: Z=0.69(P=0.49)  
   
1.3.3 Depressive symptoms at the end of treatment (final measurements)  
*Evins 2005 25 6.9 (5.8) 28 7.2 (4.8) 39.1% -0.06[-0.59,0.48]
*Evins 2007 25 10 (6.4) 26 11 (6.6) 37.63% -0.15[-0.7,0.4]
*George 2002 16 5.4 (5.1) 16 7.5 (6.4) 23.28% -0.35[-1.05,0.35]
Subtotal *** 66   70   100% -0.16[-0.5,0.18]
Heterogeneity: Tau2=0; Chi2=0.44, df=2(P=0.8); I2=0%  
Test for overall effect: Z=0.94(P=0.35)  
Favours bupropion 10.5-1 -0.5 0 Favours control
 
 
Analysis 1.4.   Comparison 1 Bupropion versus placebo, Outcome 4
Reduction - Expired CO level at the end of treatment (secondary outcome).
Study or subgroup Bupropion Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.4.1 Studies using final measurements  
*Evins 2007 25 10 (9.8) 26 15 (14.8) 40.19% -5[-11.87,1.87]
*Evins 2005 25 16 (10) 28 23 (13) 49.17% -7[-13.21,-0.79]
Subtotal *** 50   54   89.36% -6.1[-10.71,-1.49]
Heterogeneity: Tau2=0; Chi2=0.18, df=1(P=0.67); I2=0%  
Test for overall effect: Z=2.6(P=0.01)  
   
1.4.2 Studies using change from baseline  
*Evins 2001 10 12.2 (14.8) 9 27 (14.8) 10.64% -14.8[-28.15,-1.45]
Subtotal *** 10   9   10.64% -14.8[-28.15,-1.45]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.17(P=0.03)  
   
Total *** 60   63   100% -7.03[-11.38,-2.67]
Heterogeneity: Tau2=0; Chi2=1.64, df=2(P=0.44); I2=0%  
Test for overall effect: Z=3.16(P=0)  
Test for subgroup differences: Chi2=1.46, df=1 (P=0.23), I2=31.44%  
Favours bupropion 2010-20 -10 0 Favours placebo
 
 
Analysis 1.5.   Comparison 1 Bupropion versus placebo, Outcome 5
Reduction - Expired CO level at 6-month follow-up (secondary outcome).
Study or subgroup Bupropion Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.5.1 Studies using final measurements  
*Evins 2005 25 26 (16) 28 20 (12) 35.4% 6[-1.69,13.69]
*Evins 2007 25 14 (10.8) 26 24 (14.4) 36.27% -10[-16.98,-3.02]
Favours buproprion 2010-20 -10 0 Favours placebo
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Study or subgroup Bupropion Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Subtotal *** 50   54   71.67% -2.08[-17.76,13.59]
Heterogeneity: Tau2=113.97; Chi2=9.12, df=1(P=0); I2=89.04%  
Test for overall effect: Z=0.26(P=0.79)  
   
1.5.2 Studies using change from baseline  
*Evins 2001 10 12.7 (14.3) 9 27 (14.3) 28.33% -14.3[-27.2,-1.4]
Subtotal *** 10   9   28.33% -14.3[-27.2,-1.4]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=2.17(P=0.03)  
   
Total *** 60   63   100% -5.55[-17.89,6.78]
Heterogeneity: Tau2=96.5; Chi2=11.77, df=2(P=0); I2=83.01%  
Test for overall effect: Z=0.88(P=0.38)  
Test for subgroup differences: Chi2=2.65, df=1 (P=0.1), I2=62.19%  
Favours buproprion 2010-20 -10 0 Favours placebo
 
 
Analysis 1.6.   Comparison 1 Bupropion versus placebo, Outcome 6 Reduction -
Change in number of CPD from baseline at the end of treatment (secondary outcome).
Study or subgroup Bupropion Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
*Evins 2007 25 -21 (17) 26 -11 (38.1) 10.97% -10[-26.09,6.09]
*Evins 2005 25 -26.5 (16.5) 28 -10.2 (13) 30.7% -16.3[-24.36,-8.24]
*Li 2009 40 -18 (8) 40 -10 (9) 58.33% -8[-11.73,-4.27]
   
Total *** 90   94   100% -10.77[-16.52,-5.01]
Heterogeneity: Tau2=11.15; Chi2=3.36, df=2(P=0.19); I2=40.41%  
Test for overall effect: Z=3.67(P=0)  
Favours bupropion 2010-20 -10 0 Favours placebo
 
 
Analysis 1.7.   Comparison 1 Bupropion versus placebo, Outcome 7 Reduction -
Change in number of CPD from baseline at 6-month follow-up (secondary outcome).
Study or subgroup Bupropion Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
*Evins 2007 25 -9.5 (22.5) 26 -2.9 (52) 7.86% -6.6[-28.45,15.25]
*Evins 2005 25 -5 (13.7) 28 -6 (9.3) 92.14% 1[-5.38,7.38]
   
Total *** 50   54   100% 0.4[-5.72,6.53]
Heterogeneity: Tau2=0; Chi2=0.43, df=1(P=0.51); I2=0%  
Test for overall effect: Z=0.13(P=0.9)  
Favours bupropion 2010-20 -10 0 Favours placebo
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. exp schizophrenia/
2. exp paranoid-disorders/
3. schizo*.mp.
4. hebephreni*.mp.
5. oligophreni*.mp.
6. Psychotic*.mp.
7. psychosis.mp.
8. psychoses.mp.
9. chronic*.mp.
10. sever*.mp.
11. mental*.mp.
12. ill*.mp.
13. disorder*.mp.
14. ((chronic* or sever*) adj mental* adj (ill* or disorder*)).mp.
15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 14
16. tardiv*.mp.
17. dyskine*.mp.
18. (tardiv* adj dyskine*).mp.
19. akathisi*.mp.
20. acathisi*.mp.
21. neuroleptic*.mp.
22. malignant.mp.
23. syndrome.mp.
24. 21 and (malignant adj syndrome).mp.
25. movement.mp.
26. disorder*.mp.
27. 21 and 25 and 26
28. parkinsoni*.mp.
29. neuroleptic-induc*.mp.
30. parkinson's.m_titl.
31. disease.m_titl.
32. (parkinson's adj disease).m_titl.
33. 18 or 19 or 20 or 24 or 27 or 28 or 29
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34. 33 not 32
35. exp dyskinesia-drug-induced/
36. exp akathisia-drug-induced/
37. exp neuroleptic-malignant-syndrome/
38. 34 or 35 or 36 or 37
39. 38 or 15
40. smoking cessation.mp.
41. smoking-cessation/ or tobacco-use-disorder/
42. tobacco/
43. nicotine/
44. tobacco, -smokeless/
45. exp Smoking/th, pc [Therapy, Prevention & Control]
46. ((quit$ or stop$ or ceas$ or giv$) adj smok$).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
47. tobacco-smoke-pollution/
48. 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47
49. smoking/
50. 49 or 48
51. randomized controlled trial.pt.
52. controlled clinical trial.pt.
53. randomized.ab.
54. placebo.ab.
55. clinical trials as topic.sh.
56. randomly.ab.
57. trial.ti.
58. 52 or 53 or 57 or 56 or 51 or 55 or 54
59. (animals not (human and animals)).sh.
60. 58 not 59
61. 60 and 50 and 39
Appendix 2. EMBASE search strategy
1. random$.af.
2. factorial$.af.
3. crossover$.af.
4. cross over$.af.
5. cross-over$.af.
6. placebo$.af.
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7. (doubl$ adj blind$).af.
8. (singl$ adj blind$).af.
9. assign$.af.
10. allocat$.af.
11. volunteer$.af.
12. crossover procedure/
13. double blind procedure/
14. Randomized Controlled Trial/
15. Single Blind Procedure/
16. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
17. smoking cessation.mp.
18. exp smoking cessation/
19. exp smoking-/
20. ((quit$ or stop$ or ceas$ or giv$ or prevent$) adj smok$).mp. [mp=title, abstract, subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer name]
21. exp passive-smoking/ or exp smoking-habit/ or exp cigarette-smoking/ or exp "smoking-cessation"/
22. 17 or 18 or 19 or 20 or 21
23. schizo*.mp.
24. Psychotic*.mp.
25. psychosis.mp. or Psychosis/
26. psychoses.mp.
27. 26 or 23 or 25 or 24
28. exp Schizophrenia/
29. exp Psychosis/
30. chronic*.mp.
31. severe*.mp.
32. persistent*.mp.
33. mental*.mp.
34. psychological*.mp.
35. disorder*.mp.
36. ill*.mp.
37. ((chronic* or severe* or persistent*) adj (mental* or psychological*) adj (disorder* or ill*)).mp.
38. "mental-patient".mp. or exp Mental Patient/
39. tardiv*.mp.
40. dyskine*.mp.
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41. (tardiv* adj dyskine*).mp.
42. akathisi*.mp.
43. neuroleptic*.mp.
44. malignant.mp.
45. syndrome.mp.
46. 43 and (malignant adj syndrome).mp.
47. exp Tardive Dyskinesia/
48. exp Akathisia/
49. acathisia.mp.
50. exp Neuroleptic Malignant Syndrome/
51. movement.mp.
52. disorder.mp.
53. 43 and 51 and 52
54. 27 or 28 or 29 or 37 or 38
55. parkinsoni*.mp.
56. neuroleptic-induced.mp.
57. 41 or 42 or 46 or 47 or 48 or 49 or 50 or 53 or 55 or 56
58. parkinson's.m_titl.
59. 57 not 58
60. 59 or 54
61. 22 and 60 and 16
Appendix 3. PsycINFO search strategy
1. schizo*.mp.
2. hebephreni*.mp.
3. oligophreni*.mp.
4. Psychotic*.mp.
5. psychosis.mp.
6. psychoses.mp.
7. chronic*.mp.
8. sever*.mp.
9. mental*.mp.
10. ill*.mp.
11. disorder*.mp.
12. ((chronic* or sever*) adj mental* adj (ill* or disorder*)).mp.
13. exp schizophrenia/
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14. exp psychosis/
15. exp schizoaFective disorder/
16. 1 or 2 or 3 or 4 or 5 or 6 or 12 or 13 or 14 or 15
17. tardiv*.mp.
18. dyskine*.mp.
19. (tardiv* adj dyskine*).mp.
20. akathisi*.mp.
21. acathisi*.mp.
22. neuroleptic*.mp.
23. malignant.mp.
24. syndrome.mp.
25. 22 and (malignant adj syndrome).mp.
26. movement.mp.
27. disorder*.mp.
28. 22 and 26 and 27
29. parkinsoni*.mp.
30. neuroleptic-induc*.mp.
31. parkinson's.m_titl.
32. disease.m_titl.
33. (parkinson's adj disease).m_titl.
34. 19 or 20 or 21 or 25 or 28 or 29 or 30
35. 34 not 33
36. exp Neuroleptic Malignant Syndrome/
37. exp dyskinesia/
38. exp akathisia/
39. exp parkinsonism-/
40. 35 or 36 or 37 or 38 or 39
41. 40 or 16
42. smoking cessation.mp. or exp smoking cessation/
43. (antismoking or anti-smoking).mp.
44. (quit$ or cessat$).mp.
45. (abstin$ or abstain$).mp.
46. (control$ adj smok$).mp. [mp=title, abstract, heading word, table of contents, key concepts]
47. exp behavior modification/
48. 43 or 44 or 45 or 46 or 47
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49. tobacco-smoking/
50. (smok$ or cigar$ or tobacco$).mp.
51. prevention/
52. 49 or 50
53. 48 and 52
54. 51 and 52
55. 42 or 53 or 54
56. randomi*.mp.
57. singl*.mp.
58. doubl*.mp.
59. trebl*.mp.
60. tripl*.mp.
61. blind*.mp.
62. mask*.mp.
63. ((singl* or doubl* or trebl* or tripl*) adj (blind* or mask*)).mp.
64. CLIN*.mp.
65. trial*.mp.
66. (CLIN* adj trial*).mp.
67. placebo*.mp.
68. exp Placebo/
69. crossover.mp.
70. exp Treatment EFectiveness Evaluation/
71. exp mental health program evaluation/
72. random*.mp.
73. assign*.mp.
74. allocat*.mp.
75. (random* adj (assign* or allocat*)).mp.
76. 75 or 71 or 70 or 69 or 68 or 67 or 66 or 63 or 56
77. 76 and 55 and 41
W H A T ' S   N E W
 
Date Event Description
16 February 2011 Amended Date for assessed as up-to-date corrected
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H I S T O R Y
Protocol first published: Issue 3, 2008
Review first published: Issue 6, 2010
 
Date Event Description
7 July 2010 Amended Graph label corrected
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